

1 **Maternal Circulating MiRNAs That Predict Infant FASD Outcomes**

2 **Influence Placental Maturation**

3

4 **Running Title:** MicroRNAs Control The Placental Response To Alcohol

5 **Keywords:** microRNA, placenta, EMT, trophoblast, fetal growth restriction

6

7 ¹Alexander M. Tseng, ¹Amanda H. Mahnke, ^{2,3}Alan B. Wells, ¹Nihal A. Salem, ⁴Andrea M. Allan,

8 ⁵Victoria H.J. Roberts, ⁶Natali Newman, ⁶Nicole A.R. Walter, ⁶Christopher D. Kroenke, ⁶Kathleen

9 A. Grant, ⁷Lisa K. Akison, ⁷Karen M. Moritz, ^{2,3†}Christina D. Chambers, ^{1†}Rajesh C. Miranda &

10 #CIFASD

11

12 ¹Department of Neuroscience and Experimental Therapeutics, Texas A&M University Health

13 Science Center, Bryan, TX, USA

14 ²Clinical and Translational Research Institute, University of California San Diego, San Diego, CA,

15 USA

16 ³Department of Pediatrics, University of California San Diego, San Diego, CA, USA

17 ⁴Department of Neurosciences, University of New Mexico, Albuquerque, NM, USA

18 ⁵Division of Reproductive and Developmental Sciences, Oregon National Primate Research

19 Center, Oregon Health & Science University, Portland, OR, USA

20 ⁶Division of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science

21 University, Portland, OR, USA

22 ⁷Child Health Research Centre and School of Biomedical Sciences, the University of Queensland,
23 4072, Brisbane, Australia

24 [†] Co-senior authors to whom correspondence should be addressed:

25 Dr. Rajesh Miranda,

26 email: miranda@medicine.tamhsc.edu

27 Texas A&M University Health Science Center, College of Medicine, Department of Neuroscience
28 & Experimental Therapeutics, Medical Research and Education Building 8447 Riverside
29 Parkway, Bryan, TX 77807-3260

30 Phone: 979-436-0332 Fax: 979-436-0086

31 Dr. Christina Chambers

32 email: chchambers@ucsd.edu

33 University of California San Diego, Department of Pediatrics, 9500 Gilman Drive MC 0828, La
34 Jolla, CA 92093

35 Phone: 858-246-1704, Fax: 858246-1701

36 [#]CIFASD, Collaborative Initiative on Fetal Alcohol Spectrum Disorders

37

38 **Summary:**

39 Maternal gestational circulating microRNAs, predictive of adverse infant outcomes including
40 growth deficits, following prenatal alcohol exposure, contribute to placental pathology by
41 impairing the EMT pathway in trophoblasts.

42 **Abstract**

43 Prenatal Alcohol exposure (PAE), like other pregnancy complications, can result in placental
44 insufficiency and fetal growth restriction, though the linking causal mechanisms are unclear.
45 We previously identified 11 gestationally-elevated maternal circulating miRNAs that predicted
46 infant growth deficits following PAE. Here, we investigated whether these _{HEa}miRNAs contribute
47 to the pathology of PAE, by inhibiting trophoblast epithelial-mesenchymal transition (EMT), a
48 pathway critical for placental development. We now report for the first time, that PAE inhibits
49 expression of placental pro-EMT pathway members in both rodents and primates, and that
50 _{HEa}miRNAs collectively, but not individually, mediate placental EMT inhibition. _{HEa}miRNAs
51 collectively, but not individually, also inhibited cell proliferation and the EMT pathway in
52 cultured trophoblasts, while inducing cell stress, and following trophoblast syncytialization,
53 aberrant endocrine maturation. Moreover, a single intra-vascular administration of the pooled
54 murine-expressed _{HEa}miRNAs, to pregnant mice, decreased placental and fetal growth and
55 inhibited expression of pro-EMT transcripts in placenta. Our data suggests that _{HEa}miRNAs
56 collectively interfere with placental development, contributing to the pathology of PAE, and
57 perhaps also, to other causes of fetal growth restriction.

58 Introduction

59 Prenatal alcohol exposure (PAE) is common (1-3). Between 1.1-5% of school children in the
60 United States are conservatively estimated to have a Fetal Alcohol Spectrum Disorder (FASD,
61 (4)). Consequently, FASD, due to PAE, is the single largest cause of developmental disabilities in
62 the US and worldwide (5), and a co-morbid factor in a number of other prevalent
63 developmental neurobehavioral disabilities including attention deficit/hyperactivity and autism
64 spectrum disorders (6).

65 PAE can result in decreased body weight, height and/or head circumference in infants.
66 Consequently, infant growth deficits are a cardinal diagnostic feature for Fetal Alcohol
67 Syndrome (FAS, (7)), which represents the severe end of the FASD continuum . However,
68 though well-recognized as a diagnostic feature, the mechanistic linkage between PAE and
69 growth restriction remains unclear. In 2016, as part of our effort to identify maternal diagnostic
70 biomarkers of the effect of PAE, we reported that elevated levels of 11 distinct microRNAs
71 (miRNAs) in maternal circulation during the 2nd and 3rd trimesters distinguished infants who
72 were affected by *in-utero* alcohol exposure (Heavily Exposed Affected: HEa) from those who
73 were apparently unaffected at birth by PAE (Heavily Exposed Unaffected: HEua), or those who
74 were unexposed (UE) (8) . In that study, we predicted, based on bioinformatics analyses, that
75 these HEa miRNAs (MIMAT0004569 [hsa-miR-222-5p], MIMAT0004561 [hsa-miR-187-5p],
76 MIMAT0000687 [hsa-mir-299-3p], MIMAT0004765 [hsa-miR-491-3p], MIMAT0004948 [hsa-
77 miR-885-3p], MIMAT0002842 [hsa-miR-518f-3p], MIMAT0004957 [hsa-miR-760],
78 MIMAT0003880 [hsa-miR-671-5p], MIMAT0001541 [hsa-miR-449a], MIMAT0000265 [hsa-miR-
79 204-5p], MIMAT0002869 [has-miR-519a-3p]), could influence signaling pathways crucial for

80 early development, particularly the epithelial-mesenchymal transition (EMT) pathway.

81 Placental development involves maturation of cytotrophoblasts at the tips of anchoring
82 villi into invasive extravillous trophoblasts, as well as fusion of cytotrophoblasts into
83 multinucleate, hormone-producing syncytiotrophoblasts (9). Maturation into extravillous
84 trophoblasts, which invade the maternal decidua and remodel the uterine spiral arteries into
85 low-resistance high-flow vessels that enable optimal perfusion for nutrient and waste
86 exchange, requires cytotrophoblasts to undergo EMT (10). Impaired placental EMT, as well as
87 orchestration of the opposing mesenchymal-epithelial transition pathway, has been found in
88 conditions resulting from placental malfunction, primarily preeclampsia (11-16). While there
89 have been no previous studies directly investigating the effects of PAE on placental EMT, a
90 rodent study demonstrated that PAE, during a broad developmental window, reduced the
91 number of invasive trophoblasts within the mesometrial triangle, a region of the uterine horn
92 directly underlying the decidua (17). Furthermore, both human and rodent studies have found
93 PAE disrupts placental morphology, and interferes with cytotrophoblast maturation, as with
94 preeclampsia (18-21). Disrupted trophoblast maturation, seen in these conditions, is associated
95 with aberrant expression of placental hormones, primarily human chorionic gonadotropin
96 (hCG) (22-25).

97 Our study is the first to report that PAE interferes with expression of core placental EMT
98 pathway members. Using rodent and primate models of gestation, as well as complementary
99 miRNA overexpression and knockdown studies *in vitro*, we also provide evidence that
100 HEa miRNAs, which predict infant growth deficits due to PAE, collectively but not individually,
101 mediate PAE's effects on placental EMT through their effects on cytotrophoblast maturation

102 and stress. In a mouse model of pregnancy, a single combined exposure to the murine-
103 expressed $_{HEa}$ miRNAs, resulted in placental EMT inhibition, and diminished placental and fetal
104 growth. Collectively, these data suggest that elevated $_{HEa}$ miRNAs may represent an emergent
105 maternal stress response that triggers fetal growth restriction, though sub-groups of $_{HEa}$ miRNAs
106 may compete to protect against the loss of EMT. Moreover, most members of the group of
107 $_{HEa}$ miRNAs, have also been implicated in other placental insufficiency and growth restriction
108 syndromes, giving rise to the possibility that growth restriction syndromes may share common
109 etiological mediators.

110

111 **Results**

112 HEa miRNAs are implicated in placental-associated pathologies

113 Given our prediction that HEa miRNAs interfere with signaling pathways governing fetal
114 and placental development (8), we conducted a literature review of reports on HEa miRNA levels
115 in gestational pathologies caused by poor placentation (26-28). Surprisingly, placental and
116 plasma levels of 8 out of 11 HEa miRNAs were significantly dysregulated in one or more of these
117 gestational pathologies with expression of the majority of these 8 miRNAs altered in both fetal
118 growth restriction and preeclampsia (Figure 1A) (29-49), both of which are characterized by
119 poor placental invasion (50-56).

120 HEa miRNAs explain variance in infant growth outcomes due to PAE

121 Given the association of individual HEa miRNAs with gestational pathologies, we sought to
122 determine if circulating HEa miRNAs levels could explain the variance in sex and gestational age-
123 adjusted neonatal height, weight and head circumference in our Ukrainian birth cohort, which
124 are growth measures sensitive to in utero environment (57). We found that 8 of the HEa miRNAs,
125 each significantly explained between 7 to 19% of infant variation in these growth measures
126 (Table 1). Furthermore, 7 of these miRNAs were also associated with fetal growth restriction
127 and preeclampsia as identified by our literature review (Figure 1A). Interestingly, a multivariate
128 statistical regression model that accounted for levels of all 11 HEa miRNAs together, explained a
129 far greater proportion of infant variance, between 24-31%, in all three growth measures than
130 accounting for them individually (Supplementary Table 2) suggesting HEa miRNAs collectively
131 account for the variance in infant growth outcomes.

132 HEa miRNAs are transcribed preferentially in the placenta

133 Data extracted from publicly available gene expression profiling datasets (58) show that
134 $_{\text{HEa}}$ miRNAs as well as their unprocessed precursor transcripts, $_{\text{HEa}}$ pri-miRNAs, are enriched in
135 placenta compared to other tissues, suggesting that the placenta itself transcribes these
136 miRNAs and may be a significant contributory tissue to maternal circulating $_{\text{HEa}}$ miRNAs (Figures
137 1B and C). Moreover, since $_{\text{HEa}}$ miRNAs are also associated with gestational pathologies caused
138 by poor placental invasion, these $_{\text{HEa}}$ miRNAs may also contribute to the placental response to
139 PAE. We therefore assessed in rodent and primate models, whether PAE could result in
140 impaired EMT, and if $_{\text{HEa}}$ miRNAs could explain the effects of PAE on placental EMT-associated
141 gene expression.

142 $_{\text{HEa}}$ miRNAs moderate placental EMT impairment in PAE models

143 EMT, in trophoblasts, is characterized by the disappearance of epithelial markers like E-
144 Cadherin and the appearance of the mesenchymal markers like the intermediate filament,
145 Vimentin, a process that is controlled by the expression of key mesenchymal determination
146 transcription factors, Snail1 and 2 and TWIST, as extensively described (10, 14, 15, 59-62).
147 These five markers have been used extensively to assess EMT in a variety of model systems, so
148 our studies utilized these markers to assess the effects of alcohol and $_{\text{HEa}}$ miRNAs on trophoblast
149 EMT.

150 In the first analysis, using a murine model of PAE that mimicked moderate to binge-type
151 alcohol consumption throughout early and mid-pregnancy, we fractionated GD14 placenta into
152 three zones: the cytotrophoblast and syncytiotrophoblast rich labyrinth zone, the glycogen and
153 spongiotrophoblast rich junctional zone, and the decidual zone comprising the endometrial
154 contribution to the placenta (Figure 2A). Multivariate analysis of variance (MANOVA) for

155 expression of these five core genes in the EMT pathway within placental trophoblasts, revealed
156 a significant effect of ethanol exposure on EMT pathway member expression selectively within
157 the labyrinth zone (Pillai's trace statistic, $F_{(5,21)}=6.85$, $p<0.001$, Figure 2B) but not within the
158 junctional or decidual zones. Post-hoc univariate ANOVA indicated ethanol exposure specifically
159 elevated *CDH1* ($F_{(1,25)}=7.452$, $p=0.011$), which encodes epithelial E-Cadherin, whereas
160 expression of the pro-mesenchymal transcription factor *SNAI1* was significantly reduced
161 ($F_{(1,25)}=21.022$, $p=0.0001$). We also observed a significant interaction between fetal sex and PAE
162 on expression of *SNAI2* ($F_{(1,25)}=2.18$, $p=0.047$) and a trend towards decreased expression of the
163 terminal mesenchymal marker *VIM* (Vimentin, $F_{(1,25)}=2.749$, $p=0.11$), while there was no effect
164 on *TWIST* expression (Figures 3A-3E). Consistent with our gene expression data, E-Cadherin
165 protein levels were significantly elevated in the labyrinth zone of PAE placenta ($F_{(1,24)}=31.63$,
166 $p=0.0005$), while not in the junctional or decidual zones (Figure 3F and Supplementary Figures
167 3A and B). However, when we controlled for expression of the 8 mouse homologues of
168 HEa miRNAs as a covariate, using multivariate analysis of covariance (MANCOVA), ethanol's effect
169 on EMT became marginally nonsignificant (Pillai's trace, $F_{(5,21)}=2.713$, $p=0.068$) (Figure 2C),
170 suggesting that these miRNAs partially mediate effects of PAE on EMT pathway members in
171 mice. Interestingly, PAE limited to the peri-conceptual period in rats also influenced
172 expression of EMT core transcripts (Supplementary Figures 2B and 4A-4E).

173 To determine if PAE's effects on EMT pathway members in placenta are broadly
174 conserved throughout mammalian evolution, we adopted a non-human primate (macaque)
175 model of moderate to binge-type alcohol consumption. Placental tissues were isolated from
176 GD85, GD110, and GD 135 placenta (Figure 2D), which spans the human equivalent of mid-

177 second to mid-third trimester (Supplementary Figure 2C). There was a significant effect of
178 ethanol exposure on expression of core EMT mRNA transcripts by MANOVA (Pillai's trace
179 statistic, $F_{(4,9)}=4.229$ $p=0.045$, Figure 3B). Consistent with our findings in mouse, post-hoc
180 univariate ANOVA indicated that in primate placenta, ethanol exposure significantly increased
181 *CDH1* expression ($F_{(1,12)}=4.866$, $p=0.048$) whereas *VIM* expression was significantly reduced
182 ($F_{(1,12)}=12.782$, $p=0.0004$), suggesting that, as in the mouse, PAE also impairs EMT in the primate
183 placenta. Interestingly, there was no effect on *SNAI2* or *TWIST* expression (Figures 3G-3J). As in
184 mice, accounting for expression of $_{HEa}$ miRNAs together as a covariate abolished the significant
185 effect of PAE on EMT, though to a greater degree than mice (Pillai's trace, $F_{(1,1)}=1.605$, $p=0.425$,
186 Figure 2E). Interestingly, accounting for expression of individual $_{HEa}$ miRNAs did not explain the
187 effects of PAE on placental EMT, suggesting that $_{HEa}$ miRNAs act in concert to mediate the effect
188 of PAE on EMT in primate placenta (Figure 2F).

189 Collectively, our data suggests PAE induced impairment of EMT in the trophoblastic
190 compartment of placentae is conserved between rodents and non-human primates and that
191 $_{HEa}$ miRNAs, particularly in primates, may moderate the effect of PAE on placental EMT.
192 Consequently, subsequent studies focused on the collective role of $_{HEa}$ miRNAs, either on basal
193 or on alcohol-influenced placental trophoblast growth, invasion, and the maturation of
194 physiological function.

195 $_{HEa}$ miRNAs impair EMT in a model of human cytotrophoblasts

196 To investigate whether $_{HEa}$ miRNAs collectively interfere with the EMT pathway, as
197 suggested by our *in vivo* data, we examined the effects of transfecting $_{HEa}$ miRNA mimics and
198 antagomirs into BeWO cytotrophoblasts (Figure 4A). We initially overexpressed each of the 11

199 $_{HEa}$ miRNAs individually, to determine whether any of them could influence the EMT pathway.
200 We did not observe any significant effects (Supplementary Figure 5), consistent with our
201 findings in the primate PAE model that individual miRNAs did not explain the effects of ethanol
202 on EMT. In contrast, transfection of pooled $_{HEa}$ miRNAs into cytotrophoblasts significantly
203 increased *CDH1* expression ($F_{(1,36)}=30.08$, $p<0.0001$). Interestingly, expression of the pro-
204 mesenchymal transcription factors *TWIST* and *SNAI1* were also significantly reduced, but only in
205 the context of concomitant 320 mg/dL ethanol treatment, pointing to an interaction effect
206 between $_{HEa}$ miRNAs and ethanol ($F_{(1,36)}= 5.650$ and 5.146 respectively, $p=0.023$ and $p=0.029$,
207 Figures 4B-E). Consistent with our qPCR data, transfection of $_{HEa}$ miRNAs also significantly
208 increased E-cadherin protein expression ($F_{(1,20)}=33.86$, $p<0.0001$, Figure 4F). We were unable to
209 detect *SNAI2* transcript expression or vimentin protein expression in these cells, consistent with
210 previous reports (63).

211 We next sought to determine if more restricted subsets of $_{HEa}$ miRNAs could recapitulate
212 the effects of $_{HEa}$ miRNAs collectively on EMT. Thus, we overexpressed hsa-miR-222-5p and hsa-
213 miR-519a-3p, which are implicated in preeclampsia and fetal growth restriction, as well as hsa-
214 miR-885-3p, hsa-miR-518f-3p, hsa-miR-204-5p, which are implicated in preeclampsia, fetal
215 growth restriction, and spontaneous abortion or preterm labor (Supplementary Figure 6A). In
216 contrast to the collective action for all $_{HEa}$ miRNAs, exposure to each of these pools resulted in
217 significant decreases in *CDH1* expression ($F_{(2,12)}=20.12$, $p=0.0001$). The pool including hsa-miR-
218 885-3p, hsa-miR-518f-3p, hsa-miR-204-5p also significantly increased *Snai1* ($F_{(2,12)}=4.604$,
219 $p=0.0328$; Dunnett's post-hoc $p=0.0497$, Supplementary Figure 6B-E). These data suggest that
220 $_{HEa}$ miRNAs include sub-groups of miRNAs that have the potential to partly mitigate the effects

221 of elevating the entire pool. However, the potential protective effects of these sub-groups are
222 masked by the collective function of the entire group of $_{HEa}$ miRNAs.

223 Whereas transfection of $_{HEa}$ miRNA mimics increased *CDH1* expression, transfection of
224 pooled antagomirs to $_{HEa}$ miRNAs, significantly reduced *CDH1* expression, only in the context of
225 320 mg/dL ethanol co-exposure ($_{HEa}$ miRNA x 320mg/dL Etoh interaction, $F_{(1,36)}=13.51$, $p=0.0008$;
226 post-hoc Tukey's HSD, $p=0.005$, Figure 4G). However, expression of *TWIST* was also decreased
227 with ethanol co-exposure and there was no significant difference in E-Cadherin protein
228 expression relative to the control (Figure 4H-K). Thus, our data suggest that, increasing
229 $_{HEa}$ miRNA levels impairs EMT pathway members in cytotrophoblasts whereas inhibiting their
230 action has a more restricted effect on EMT pathway members.

231 $_{HEa}$ miRNAs impair EMT in a model of human extravillous trophoblasts

232 We next investigated the effect of $_{HEa}$ miRNAs on EMT in HTR-8/SVneo extravillous
233 trophoblast-type cells (Figure 5A). Transfecting pooled $_{HEa}$ miRNA mimics into extravillous
234 trophoblasts significantly decreased *VIM* expression ($F_{(1,36)}=28.43$, $p<0.0001$). Expression of pro-
235 mesenchymal transcription factors *SNAI2* was also reduced ($F_{(1,36)}=64.88$ respectively,
236 $p<0.0001$). As with cytotrophoblasts, expression of *SNAI1* and *TWIST* were reduced only with
237 320 mg/dL ethanol co-exposure ($_{HEa}$ miRNA x 320mg/dL Etoh interaction, $F_{(1,36)}=4.21$ and 5.18 ,
238 $p=0.048$ and 0.029 respectively; post-hoc Tukey's HSD, $p=0.027$ and $p<0.0001$ respectively,
239 Figures 5B-E). Consistent with our qPCR data, Vimentin protein expression was also significantly
240 reduced ($F_{(1,20)}=9.535$, $p=0.006$, Figure 5F). Interestingly, there was also a main effect of alcohol
241 exposure on decreasing vimentin protein expression ($F_{(1,20)}=7.303$, $p=0.014$). We were unable to

242 detect expression of *CDH1* transcript, or its E-Cadherin protein product, in extravillous
243 trophoblasts, consistent with previous reports (63).

244 In contrast to $_{HEa}$ miRNA mimics, transfecting pooled antagomirs significantly increased
245 *VIM* expression ($F_{(1,35)}=42.56$, $p<0.0001$). Likewise, antagomir transfection increased expression
246 of *Snai2* in the context of 320mg/dL ethanol co-exposure and *Snai1* under basal conditions
247 ($_{HEa}$ miRNA x 320mg/dL Etoh interaction, $F_{(1,35)}=10.31$ and 4.86, $p=0.01$ and $p=0.034$ respectively;
248 post-hoc Tukey's HSD, $p<0.0001$, Figures 5G-J). Despite our qPCR data, we did not observe
249 significant differences in vimentin protein expression between treatment groups (Figure 5K).
250 Collectively, our data indicate that increased trophoblastic $_{HEa}$ miRNA levels favors an epithelial
251 phenotype, whereas inhibiting their action promotes a mesenchymal phenotype.

252 Antagomirs prevent $_{HEa}$ miRNAs' inhibition of EMT

253 We next investigated if pretreating cytotrophoblasts with pooled $_{HEa}$ miRNA antagomirs
254 could prevent inhibition of the EMT pathway caused by transfecting $_{HEa}$ miRNA mimics.
255 Pretreatment of cytotrophoblasts with $_{HEa}$ miRNA antagomirs prevented the elevation in *CDH1*
256 caused by transfection with $_{HEa}$ miRNA mimics (post-hoc Tukey's HSD, $n=10$ samples per group,
257 $p=0.004$). Likewise, pre-transfection with $_{HEa}$ miRNA antagomirs also prevented $_{HEa}$ miRNA mimic
258 induced reduction of *SNAI1* and *VIM* expression (post-hoc Tukey's HSD, $n=10$ samples per
259 group, $p=0.007$ and $p<0.0001$ respectively) (Figure 6A-D).

260 As with cytotrophoblasts, pre-transfection with $_{HEa}$ miRNA antagomirs prevented
261 $_{HEa}$ miRNA mimic induced reduction of *VIM*, *SNAI1*, and *SNAI2* expression in extravillous
262 trophoblasts (post-hoc Tukey's HSD, $n=10$ samples per group, $p<0.0001$, Figure 6E-H). Thus, our
263 data suggest that pretreating cells with $_{HEa}$ miRNA antagomirs prevents inhibition of EMT

264 pathway members resulting from transfection with $_{HEa}$ miRNA mimics in cytotrophoblasts and
265 extravillous trophoblasts.

266 $_{HEa}$ miRNAs impair extravillous trophoblast invasion

267 Functionally, inhibition of the EMT pathway should reduce trophoblast invasiveness.

268 Thus, we performed a transwell invasion assay using HTR8 extravillous trophoblasts transfected
269 with $_{HEa}$ miRNA mimics and antagomirs. While ethanol exposure by itself did not impair
270 trophoblast invasion (Supplementary Figure 7), there was a marginally significant interaction
271 effect between ethanol exposure and $_{HEa}$ miRNA mimic transfection ($F_{(1,28)}=3.418$, $p=0.075$).

272 Thus, a planned comparison indicated that transfection with $_{HEa}$ miRNA mimics significantly
273 reduced trophoblast invasion in the context of 320 mg/dL ethanol co-exposure, relative to the
274 control mimics ($t(14)=2.762$, $p=0.015$), consistent with our data demonstrating $_{HEa}$ miRNAs
275 interfere with the EMT pathway (Figure 7A). Contrastingly, transfecting $_{HEa}$ miRNA antagomirs
276 increased invasion in the context of 320 mg/dL ethanol co-exposure, though this effect was
277 only marginally significant ($t(14)=1.805$, $p=0.093$, Figure 7B).

278 $_{HEa}$ miRNAs retard trophoblast cell cycle progression

279 Given the proliferative nature of cytotrophoblasts, and the intimate relationship
280 between EMT and cell cycle (64, 65), we assessed the effects of ethanol and $_{HEa}$ miRNAs on
281 BeWO cytotrophoblast cell cycle. After pulse-labeling cells with the nucleic acid analog, EdU, for
282 1-hour, we found that individually transfecting 6 of the $_{HEa}$ miRNA mimics increased EdU
283 incorporation (Unpaired t-test, $p<0.05$, FDR correction), suggesting an overall increased rate of
284 DNA synthesis (Supplementary Figure 8A). Contrastingly, simultaneous transfection of
285 $_{HEa}$ miRNAs significantly reduced EdU incorporation ($F_{(1,26)}=59.69$, $p<0.0001$), mirroring the

286 effects of increasing concentrations of ethanol ($R^2=0.304$, $p=0.012$) (Supplementary Figure 8B
287 and Figure 8A).

288 Consistent with the increased rates of DNA synthesis resulting from individual $_{HEa}$ miRNA
289 mimic transfection, individual transfection of $_{HEa}$ miRNAs antagomirs generally reduced EdU
290 incorporation, though only the antagomir to hsa-miR-760 did so significantly ($t(110)=3.059$,
291 $p=0.003$, FDR correction) (Supplementary Figure 8A). Interestingly, simultaneous administration
292 of antagomirs also reduced EdU incorporation, as observed with the pooled $_{HEa}$ miRNAs mimics
293 ($F_{(1,26)}=34.83$, $p=0.0005$, Figure 8B).

294 To further characterize the coordinated effect of $_{HEa}$ miRNAs on cytotrophoblast cell
295 cycle, we pulse-labeled cells with EdU for 1-hour and, post-fixation, labelled them with 7AAD to
296 segregate cells into three groups: G_0/G_1 (7AADlow, EDU-), S (EDU+), and G_2/M (7AADhigh, EDU-
297). Both 120 mg/dL and 320 mg/dL ethanol exposures significantly decreased the proportion of
298 cells in S-phase, while 320 mg/dL exposure increased the proportion of cells in G_2/M -phase,
299 consistent with the observed reduction in the rate of DNA synthesis (Supplementary Figure 8C).
300 Similar, to the effects of ethanol exposure, pooled $_{HEa}$ miRNA mimic administration also
301 significantly decreased the proportion of cells in S-phase ($F_{(1,28)}=52.78$, $p<0.0001$) while
302 increasing the proportion of cells the G_2/M -phase ($F_{(1,28)}=8.395$, $p=0.007$) and exacerbated
303 alcohol's effects on the cell cycle (Figure 8C). Interestingly, pooled $_{HEa}$ miRNA antagomir
304 administration also reduced the proportion of cells in S-phase ($F_{(1,26)}=14.98$, $p=0.0007$) and
305 increased the proportion of those in G_2/M -phase ($F_{(1,26)}=12.38$, $p=0.002$) (Figure 8D).

306 As with our EMT gene expression data, pretreatment of cytotrophoblasts with
307 antagomirs $_{HEa}$ miRNA prevented further reduction in the rate of DNA synthesis, or cell cycle

308 retardation, that would result from transfection with pooled $_{HEa}$ miRNA mimics (Figures 9A and
309 B).

310 $_{HEa}$ miRNAs have minimal effect on cell survival

311 We next investigated whether ethanol- and $_{HEa}$ miRNA-induced changes in cell cycle were
312 related to an increase in cell death. Only the 320 mg/dL dose of ethanol exposure
313 demonstrated a slight, but marginally significant effect, of increasing lytic cell death
314 ($t(18)=2.022$, $p=0.054$), though there was no effect on apoptosis (Supplementary Figures 9A and
315 B). However, the changes in cell cycle following transfection of individual or pooled $_{HEa}$ miRNA
316 mimics were not mirrored by changes in lytic cell death. Nevertheless, two $_{HEa}$ miRNAs, hsa-mir-
317 671-5p and hsa-mir-449a, did significantly increase apoptosis (Unpaired t-test, $p<0.05$, FDR
318 correction) (Supplementary Figures 9C and D).

319 Contrastingly, transfection of 4 $_{HEa}$ miRNA antagonists individually, significantly increased
320 lytic cell death (Unpaired t-test, all $p<0.05$, FDR correction), with the antagonist to hsa-mir-491-
321 3p also increasing apoptotic cell death ($t(14)=3.383$, $p=0.004$, FDR correction, Supplementary
322 Figure 9C and D). Likewise, transfection of pooled $_{HEa}$ miRNA antagonists increased lytic cell
323 death ($F_{(1,36)}=11.40$, $p=0.002$) but did not cause increased apoptosis (Supplementary Figure 9E-
324 H). Taken together, our data suggest that while ethanol exposure may increase cytotrophoblast
325 death, increased levels of $_{HEa}$ miRNAs have minimal effects on cell death, suggesting that their
326 effect on cell cycle and the EMT pathway is independent of any effect on cell survival.

327 $_{HEa}$ miRNAs modulate cytotrophoblast differentiation-associated Ca^{2+} dynamics

328 $_{HEa}$ miRNAs' effects on EMT pathway member expression, coupled with cell cycle
329 retardation, indicates that $_{HEa}$ miRNAs influence trophoblast maturation. To model $_{HEa}$ miRNAs'

330 effect on hormone-producing and calcium-transporting syncytiotrophoblasts (66), we used a
331 well-established protocol of forskolin induced syncytialization of BeWO cytotrophoblasts (67,
332 68). As expected, forskolin treatment induced fusion/syncytialization of cytotrophoblasts
333 resulting in a greater average cell size in the forskolin + $_{HEa}$ miRNA mimics group ($F_{(1,386)}=4.386$,
334 $p=0.037$). This suggests that the inhibition of EMT by these miRNAs may result in preferential
335 syncytialization instead of differentiation to extravillous trophoblasts (Supplementary Figure
336 10A). Ethanol and forskolin treatment both increased baseline calcium levels, as indicated by
337 the change in fluo-4 fluorescence ($F_{(1,426)}=5.593$ and 3.665 respectively, $p<0.0001$, Figure 10A,
338 Supplementary Figures 10B-D). The effect of ethanol on baseline calcium was abrogated by
339 $_{HEa}$ miRNAs while $_{HEa}$ miRNAs + forskolin was not significantly different to forskolin alone,
340 indicating that forskolin and $_{HEa}$ miRNAs may be affecting similar calcium pathways. The
341 conversion of cytotrophoblasts to syncytiotrophoblasts is accompanied by an increase in
342 endoplasmic reticulum, which could increase calcium buffering capabilities in response to
343 ethanol-stress on the cells, thus $_{HEa}$ miRNA-induced syncytialization pathways may be protective
344 against ethanol stress.

345 Adaptations to cellular stress can also be seen in alterations to cellular energetics in
346 response to ethanol, as ethanol-exposed BeWO cells showed decreased baseline and stressed
347 oxygen consumption rates (OCR) ($F_{(1,28)}=15.55$ and 16.91 , $p=0.0005$ and 0.0003 respectively)
348 and increased extracellular acidification rates (ECAR) ($F_{(1,28)}=4.868$, $p=0.036$). However,
349 $_{HEa}$ miRNAs had minimal effects on metabolic activity (Figures 10D-10G).

350 Extracellular ATP has been shown to inhibit trophoblast migration (69) and can directly
351 stimulate increased intracellular calcium elevations through purinergic receptors ubiquitously

352 present on trophoblasts (70). Both $_{HEa}$ miRNA and ethanol administration significantly increased
353 intracellular calcium in response to acute ATP administration ($F_{(1,426)}=10.34$ and $F_{(1,386)}=16.30$,
354 $p=0.001$ and $p<0.0001$ respectively) (Figure 10B). This may be indicative of a lack of
355 downregulation of purinergic receptors required in trophoblast migration as part of the
356 interrupted EMT pathway. Forskolin-induced maturation decreased calcium response to ATP
357 ($F_{(1,386)}=50.72$, $p<0.0001$) (Figure 10C) and prevented the $_{HEa}$ miRNA-induced increase in ATP
358 response. These data agree with previous studies showing increased nuclear trafficking of
359 ionotropic receptor P2X7 and more localized P2X4 expression over placental development,
360 which may decrease the overall calcium influx in response to ATP (71).

361 $_{HEa}$ miRNAs promotes syncytialization-dependent hormone production

362 Transfection of $_{HEa}$ miRNA mimics did not change *CGA*, *CGB*, or *IGF2* transcript expression
363 relative to the control in non-syncytialized trophoblasts. However, following forskolin induced
364 syncytialization of BeWO cytotrophoblasts (Figure 11A), $_{HEa}$ miRNA mimics significantly
365 increased expression of *CGA* and *CGB* (post-hoc Tukey's HSD, $n=10$ samples per group, $p=0.001$
366 and 0.005 respectively). Consistent with our previous results, $_{HEa}$ miRNA mimics also increased
367 *CDH1* expression in both cytotrophoblasts and syncytiotrophoblasts ($F_{(1,20)}=5.286$, $p=0.032$);
368 there was also a main effect of syncytialization on *CDH1* expression, as has been previously
369 reported ($F_{(1,36)}=3.391$, $p=0.034$, Figures 11B-E). Likewise, $_{HEa}$ miRNAs increased E-cadherin
370 protein expression ($F_{(1,20)}=5.286$, $p=0.032$), whereas forskolin decreased it ($F_{(1,20)}=10.24$,
371 $p=0.005$) (Figure 11F). On the other hand, there was no effect of $_{HEa}$ miRNA antagonists on *CGA*
372 and *CGB* expression, although we did observe a decrease in *IGF2* transcript expression,

373 following syncytialization, relative to controls (post-hoc Tukey's HSD, n=10 samples per group,
374 p=0.001) (Figure 11G-J).

375 Given that $_{HEa}$ miRNAs promotes syncytialization-dependent hormone production, we
376 next investigated maternal plasma levels of intact human chorionic gonadotropin (hCG) in our
377 Ukraine birth cohort. Plasma hCG levels were non-significantly increased in the second
378 trimester of HEa group mothers relative to their UE counterparts, consistent with previous
379 studies (72). During the third trimester, however, hCG levels remained significantly elevated in
380 HEa group mothers compared to the UE group (Median Test, n=23 samples in HEa group and
381 n=22 for HEua and HEa groups, p=0.03) (Figure 12). Furthermore, there was no significant
382 difference of gestational age at blood draw between the different groups indicating the
383 increased level of hCG in the HEa group was not confounded by gestational age at which blood
384 was sampled (Supplementary Figure 11) (73). Interestingly, both alcohol and hCG levels were
385 negatively associated with gestational age at delivery (GAD), with a significant interaction
386 between periconceptional alcohol exposure and hCG levels on GAD (Supplementary Table 3).
387 Taken together, our data suggests $_{HEa}$ miRNAs may contribute to PAE-dependent increases in
388 hCG levels during pregnancy.

389 $_{HEa}$ miRNAs reduce fetal growth

390 To investigate the functional consequences of elevated circulating $_{HEa}$ miRNA levels, we
391 administered miRNA mimics for the 8-mouse homologue $_{HEa}$ miRNAs, or a negative control
392 mimic, through tail-vein injection to pregnant mouse dams on GD10. On GD18, growth
393 parameters of male and female fetuses were assessed separately, and data from all same-sex
394 fetuses from a single pregnancy were averaged into one data point. Dams administered

395 $_{HEa}$ miRNA mimics produced smaller fetuses than those administered control mimics, according
396 to all collected measures of fetal size: fetal weight ($F_{(1,17)}=9.92$, $p=0.006$), crown-rump length
397 ($F_{(1,17)}=9.89$, $p=0.006$), snout-occipital distance ($F_{(1,17)}=9.09$, $p=0.008$), and biparietal diameter
398 ($F_{(1,17)}=5.99$, $p=0.026$) (Figure 13B-E). Interestingly, placental weights were also significantly
399 reduced in mice treated with $_{HEa}$ miRNA mimics ($F_{(1,17)}=6.92$, $p=0.018$) (Figure 13F).

400 Following tail-vein administration of two human-specific sentinel miRNAs, miR-518f-3p
401 and miR-519a-3p, we found a high biodistribution of both miRNAs in the placenta, comparable
402 to levels seen in the liver and spleen (Supplementary Figure 12A and 12B). Thus, to determine
403 whether $_{HEa}$ miRNA's effects on fetal growth could result from their actions on the placenta, we
404 quantified the placental expression of core EMT members in the GD18 placentas of control and
405 $_{HEa}$ miRNA fetuses. $_{HEa}$ miRNA administration significantly reduced expression of mesenchymal-
406 associated transcript *VIM* ($F_{(1,14)}=14.23$, $p=0.002$) and *SNAI2* ($F_{(1,14)}=5.99$, $p=0.028$) with a
407 significant sex by $_{HEa}$ miRNA interaction effect on *SNAI1* ($F_{(1,66)}=5.55$, $p=0.034$) and *CDH1*
408 ($F_{(1,14)}=6.01$, $p=0.028$) (Figures 14A-E). Interestingly, and in line with our *in vitro* findings
409 whereby $_{HEa}$ miRNAs promoted syncytialization dependent cell fusion and hCG production,
410 $_{HEa}$ miRNA administration significantly increased expression of the mRNA transcript for *SynB*, a
411 gene that is important for syncytiotrophoblast maturation ($F_{(1,66)}=4.11$, $p=0.047$) (Figure 14F).

412 **Discussion**

413 We previously reported that gestational elevation of 11 maternal plasma miRNAs
414 predicted which PAE infants would exhibit adverse outcomes at birth (8). These _{HEa}miRNAs
415 were elevated throughout mid and late-pregnancy, encompassing critical periods for fetal
416 development, and were predicted to target the EMT pathway (8). In this study, we tested this
417 prediction by adopting rodent and macaque gestational moderate alcohol self-administration
418 paradigms. Despite differences in their placental anatomy (74-77), we are the first to report
419 that PAE impairs placental EMT across species, indicating a conserved effect of PAE on placental
420 development. Additionally, we found that _{HEa}miRNAs collectively, but not individually,
421 mediated the effects of PAE on core EMT pathway members and that, together, they inhibited
422 EMT in human trophoblast culture models. While we assessed the effects of _{HEa}miRNAs on core
423 EMT components (10, 14, 15, 59-62), analysis of their 3'UTRs indicates that these are unlikely to
424 be the direct targets of _{HEa}miRNA action. Additional studies will be needed to dissect out the
425 signaling networks that connect _{HEa}miRNAs to the assessed EMT components.

426 Interestingly, _{HEa}miRNAs also promoted syncytialization (forskolin)-dependent hCG
427 expression, mirroring the elevation of third trimester maternal hCG levels in the PAE group
428 within our clinical cohort. This late-gestation elevation of hCG levels may serve as a
429 compensatory mechanism to prevent the preterm birth associated with PAE, as hCG during late
430 gestation is hypothesized to promote uterine myometrial quiescence (78, 79). In support of this
431 hypothesis, we found significant negative associations between both hCG levels and alcohol
432 consumption with gestational age at delivery. Furthermore, there was a significant interaction
433 between periconceptional alcohol exposure and hCG levels, with higher hCG levels

434 corresponding to a smaller effect of alcohol exposure at conception on gestational age at
435 delivery, indicating that hCG moderates the effect of alcohol on age at delivery (Supplementary
436 Table 3).

437 Since $_{HEa}$ miRNAs collectively prevented trophoblast EMT, we hypothesized that, as a
438 functional consequence, these maternal miRNAs would also inhibit fetal growth. When we
439 delivered 8 out of the 11 $_{HEa}$ miRNAs known to be present in mouse, to pregnant dams during
440 the period of placental branching morphogenesis and endometrial invasion, when EMT is
441 particularly active, we found that $_{HEa}$ miRNAs reduced fetal growth. Importantly, ethanol
442 exposure during this period has also been shown to result in fetal growth deficits and
443 dysmorphia in rodent PAE models (80, 81) suggesting that maternal miRNA-mediated deficits in
444 trophoblast invasion may mediate some of the effects of PAE on fetal growth. In support of this,
445 we found placentas from the $_{HEa}$ miRNA treated group had impaired expression of core EMT
446 pathway members. This disruption of placental EMT may also have implications for placental
447 vascular dynamics, as we have also previously observed in mouse models (82). The non-human
448 primate tissue analyzed here was also derived from animals that were characterized *in vivo*
449 using MRI and ultrasound imaging, which demonstrated that maternal blood supply to the
450 placenta was lower in ethanol-exposed animals compared to controls, and that oxygen
451 availability to the fetal vasculature was reduced (83).

452 $_{HEa}$ miRNAs may mediate other pregnancy associated pathologies, aside from PAE. We
453 identified numerous studies that reported increased circulating and placental levels of at least 8
454 out of 11 $_{HEa}$ miRNAs in gestational pathologies arising from placental dysfunction. For example,
455 elevated levels of one $_{HEa}$ miRNA, miR-519a-3p, a member of the placentally-expressed C19MC

456 family cluster, was reported in placentae of patients with pre-eclampsia, recurrent spontaneous
457 abortion, and intrauterine growth restriction (29, 30, 45, 46). Interestingly, collective
458 overexpression of the 59 C19MC miRNAs inhibits trophoblast migration, explaining their
459 enrichment in the non-migratory villous trophoblasts and suggests their downregulation is
460 necessary for maturation into invasive extravillous trophoblasts (84). Thus, a greater
461 understanding of the placental roles of $_{HEa}$ miRNAs may also help disentangle the etiology of
462 other pregnancy complications. We also observed that overexpression of more restricted
463 subsets of $_{HEa}$ miRNAs associated with preeclampsia, fetal growth restriction, and spontaneous
464 abortion or preterm labor also partly promoted EMT transcript signatures, contrasting with the
465 collective inhibitory action of $_{HEa}$ miRNAs as a whole. Thus, elevation of some subsets of
466 $_{HEa}$ miRNAs may constitute a compensatory mechanism aimed at minimizing placental
467 pathologies, though their potential protective effects are masked by the collective elevation of
468 $_{HEa}$ miRNAs.

469 While we did not investigate the effects of PAE on EMT in non-placental organs, it is
470 likely that PAE broadly disrupts EMT in multiple fetal compartments. Developmental ethanol
471 exposure has been shown inhibit the EMT-dependent migration of neural crest progenitors
472 involved in craniofacial development, explaining the facial dysmorphology seen in FAS and
473 FASDs (85, 86). Outside of its effects on the neural crest, PAE is significantly associated with
474 various congenital heart defects, including both septal defects and valvular malformations (87-
475 90). Given that development of heart depends on EMT within the endocardial cushions (91, 92),
476 disruption of endocardial EMT could explain both the valvular and septal malformation
477 associated with PAE.

478 Collectively, our data on _{HEa}miRNAs suggest miRNA-based interventions could minimize
479 or reverse developmental effects of PAE and other placental-related pathologies. miRNA-based
480 therapeutic approaches have been advanced for other disease conditions(93)(94). However,
481 our data also suggests the effects of combinations of miRNAs are not a sum of their individual
482 effects. Functional synergy between clusters of co-regulated miRNAs may be a common feature
483 in development and disease. For instance, in 2007, we presented early evidence that ethanol
484 exposure reduced miR-335, -21, and -153 in neural progenitors and that coordinate reduction
485 in these miRNAs yielded net resistance to apoptosis following ethanol exposure (95). In that
486 study, we also showed that coordinate knockdown of these three miRNAs was required to
487 induce mRNA for Jagged-1, a ligand for the Notch cell signaling pathway, an outcome that was
488 not recapitulated by knocking down each miRNA individually (95). More recently, combined
489 administration of miR-21 and miR-146a has been shown to be more effective in preserving
490 cardiac function following myocardial infarction than administration of either of these miRNAs
491 alone (96). While miRNA synergy has not been explored in detail, these data show that new
492 biology may emerge with admixtures of miRNAs, and that therapeutic interventions may
493 require the use of such miRNA admixtures rather than single miRNA molecules, as have been
494 used in clinical studies to date.

495 In conclusion, we have observed that a set of 11 miRNAs, predictive of adverse infant
496 outcomes following PAE, collectively mediate the effects of alcohol on the placenta. Specifically,
497 elevated levels of these miRNAs together, but not individually, promote an aberrant
498 maturational phenotype in trophoblasts by inhibiting core members of the EMT pathway and
499 promoting cell stress and syncytialization-dependent hormone production. While extensive

500 research has established circulating miRNAs as biomarkers of disease, our study is one of the
501 first to show how these miRNAs explain and control the disease process themselves.
502 Functionally, we find that these miRNAs are clinically correlated with measures of fetal
503 development and directly cause intrauterine growth restriction when administered *in vivo*. Our
504 work suggests that a greater understanding for the role of _{HEa}miRNAs during development, and
505 their role in coordinating the EMT pathway in the placenta and other developing tissues, will
506 benefit the understanding of FASDs and other gestational pathologies and potentially lead to
507 effective avenues for intervention.

508 **Methods**

509 Mouse model of PAE:

510 C57/BL6J mice (Jackson Laboratory, Bar Harbor, ME) were housed under reverse 12-hour dark /
511 12-hour light cycle (lights off at 08:00 hours). PAE was performed using a previously described
512 limited access paradigm of maternal drinking (97, 98). Briefly, 60-day old female mice were
513 subjected to a ramp-up period with 0.066% saccharin containing 0% ethanol (2 days), 5%
514 ethanol (2 days), and finally 10% ethanol for 4-hours daily from 10:00–14:00 beginning 2 weeks
515 prior to pregnancy, continuing through gestation (Supplementary Figure 2A). Female mice
516 offered 0.066% saccharin without ethanol during the same time-period throughout pregnancy
517 served as controls. Tissue from the labyrinth, junctional, and decidual zone of male and female
518 gestational day 14 (GD14) placentae were microdissected, snap-frozen in liquid nitrogen, and
519 stored at -80°C preceding RNA and protein isolation.

520 Mouse model for _{HEa}miRNA overexpression:

521 For systemic administration of miRNAs, previously nulliparous C57/BL6NHsd dams (Envigo,
522 Houston, TX) were tail-vein-injected on GD10 with either 50 µg of miRNA miRVana™ mimic
523 negative control (Thermo Fisher, Waltham, MA, Cat No. 4464061) or pooled _{HEa}miRNA
524 miRVana™ mimics in In-vivo RNA-LANCER II (Bioo Scientific, Austin, TX, 3410-01), according to
525 manufacturer instructions. The 50 µg of pooled _{HEa}miRNA mimics consisted of equimolar
526 quantities of mmu-miR-222-5p, mmu-miR-187-5p, mmu-mir-299a, mmu-miR-491-3p, miR-760-
527 3p, mmu-miR-671-3p, mmu-miR-449a-5p, and mmu-miR-204-5p mimics. For bio-distribution
528 studies, 50 µg of pooled equimolar quantities of hsa-miR-519a-3p and hsa-miR-518f-3p mimics were
529 injected via tail vein. These human miRNAs were selected because no mouse homologs are known to

530 exist and consequently, estimates for organ distribution of exogenous miRNAs in the mouse are unlikely
531 to be contaminated by the expression of endogenous murine miRNAs. GD10 is a time point near the
532 beginning of the developmental period of branching morphogenesis, immediately following
533 chorioallantoic attachment, during which the placenta invades the maternal endometrium (99).
534 At GD18, pregnancies were terminated with subsequent quantification of fetal weight, crown-
535 rump length, snout-occipital distance, biparietal diameter, and placental weight (Figure 13A).
536 Subsequently, tissue was snap-frozen in liquid nitrogen, and stored at -80°C preceding RNA
537 isolation.

538 Rat model of PAE:

539 Outbred nulliparous Sprague-Dawley rats were housed under a 12-hour light/12-hour dark
540 cycle. PAE in Sprague-Dawley was conducted according to our previously published exposure
541 paradigm (20, 100). Briefly, dams were given a liquid diet containing either 0% or 12.5% ethanol
542 (vol/vol) from 4 days prior to mating until GD4 (Supplementary Figure 2B). Dams had *ad libitum*
543 access to the liquid diet 21-hours daily and consumed equivalent calories. Water offered during
544 the remaining 3-hours of the day. On GD5, liquid diets were removed and replaced with
545 standard laboratory chow. On GD20, placentas were immediately separated into the labyrinth
546 and junctional zone, snap frozen in liquid nitrogen and stored at -80 °C preceding RNA
547 isolation.

548 Non-human primate model of PAE:

549 As previously described in detail (83), adult female rhesus macaques were trained to orally self-
550 administer either 1.5 g/kg/d of 4% ethanol solution (equivalent to 6 drinks/day), or an isocaloric
551 control fluid prior to time-mated breeding. Each pregnant animal continued ethanol exposure

552 until gestational day 60 (GD60, term gestation is 168 days in the rhesus macaque) (101).
553 Pregnancies were terminated by cesarean section delivery at three different time points; GD85,
554 GD110, or GD135 (Supplementary Figure 2C). The macaque placenta is typically bi-lobed with
555 the umbilical cord insertion in the primary lobe and bridging vessels supplying the fetal side
556 vasculature to the secondary lobe (Figure 2D showing gross placenta anatomy) (102). Full
557 thickness tissue biopsies (maternal decidua to fetal membranes) were taken from both the
558 primary and secondary lobes of the placenta (Figure 2E showing H&E section of placenta).
559 Samples were immediately snap-frozen in liquid nitrogen and stored at -80°C preceding RNA
560 isolation.

561 Cell culture trophoblast models:

562 BeWO human cytotrophoblastic choriocarcinoma cells and HTR-8/SVneo extravillous cells were
563 sourced from ATCC (Manassas, VA, Cat No. CCL-98 and CRL-3271 respectively). BeWO cells
564 were maintained in HAM's F12 media containing penicillin (100 U/ml), streptomycin (100
565 µg/ml), and 10% vol/vol fetal calf serum (FCS) at 37°C and 5% CO₂. HTR8 cells were maintained
566 in RPMI-1640 media with 5% vol/vol FCS, under otherwise identical conditions. Culture medium
567 was replenished every 2 days and cells sub-cultured every 4-5 days.

568 BeWO cells were treated with 20 µm forskolin to induce syncytialization, as previously
569 described (103, 104). BeWO and HTR8 cells were also subjected to four separate ethanol
570 treatment conditions: 0 mg/dL, 60 mg/dl (13 mM), 120 mg/dl (26 mM) or 320 mg/dl (70 mM).

571 To achieve _{HEa} miRNA overexpression and inhibition, Dharmacon miRIDIAN™ miRNA mimics and
572 hairpin inhibitors [25 nM], or control mimic (Dharmacon, Lafayette CO, Cat No. CN-001000-01-
573 05) and hairpin inhibitor (Dharmacon, Cat No. CN-001000-01-05) [25nm], were transfected into

574 subconfluent BeWO and HTR8 cells using RNAiMAX lipofection reagent (Thermo Fisher, Cat No.
575 13778).

576 Cell cycle analysis:

577 At 48-hours-post transfection, BeWO cells were pulsed with 10 μ M EdU for 1-hour. Cells were
578 immediately harvested, and cell cycle analysis was performed with the Click-iT[®] EdU Alexa
579 Fluor[®] 488 Flow Cytometry Assay Kit (Thermo Fisher, Cat No. C10420), in conjunction with 7-
580 Amino-Actinomycin D (Thermo Fisher, Cat No. 00-6993-50), according to manufacturer
581 instructions, using the Beckman Coulter[®] Gallios 2/5/3 Flow Cytometer. Data was analyzed
582 using Kaluza software (Beckman Coulter, Brea, CA).

583 Cell death analysis:

584 BeWO cell culture was harvested 48-hours post transfection media was subjected to lactate
585 dehydrogenase (LDH) detection using the Pierce[™] LDH Cytotoxicity Assay Kit (Thermo Fisher,
586 Cat No. 88953), according to manufacturer instructions, for lytic cell death quantification. The
587 Promega Caspase-Glo[®] 3/7 Assay Systems (Promega, Madison, WI, Cat No. G8091) was used to
588 quantify apoptotic cell death

589 Invasion assay:

590 At 24-hours post-transfection and/or ethanol exposure, HTR8 cells were serum starved for an
591 additional 18-hours. Subsequently, HTR8 cells were seeded onto trans-well permeable supports
592 precoated with 300 μ g/mL Matrigel (Corning, Corning, NY, Cat No. 354248). After 24-hours,
593 cells remaining in the apical chamber were removed with a cotton swab. Cells that invaded into
594 the basal chamber were incubated with 1.2 mM 3-(4,5-dimethylthiazol-2-yl)-2,5-

595 diphenyltetrazolium bromide (MTT) for 3-hours, and the precipitate solubilized with 10% SDS in
596 0.01N HCl. Absorbance intensities were read at 570 nm in a Tecan Infinite® 200 plate reader.

597 Metabolic flux analysis and calcium imaging:

598 BeWO cells (10,000/well) were plated into Seahorse XF96 Cell Culture Microplates (Agilent
599 Biotechnology, Cat No. 103275-100). The oxygen consumption rate (OCR), a measure of
600 mitochondrial respiration, and extracellular acidification rate (ECAR), a measure of glycolysis,
601 were measured using the Seahorse XFe96 flux analyzer (Seahorse Bioscience, North Billerica,
602 MA). At the time of assay, cell culture medium was replaced with the appropriate pre-warmed
603 Seahorse XF Base Medium (Agilent Biotechnology, Santa Clara, CA, Cat No. 102353-100). OCR
604 and ECAR parameters were measured using the Seahorse XFp Cell Energy Phenotype Test Kit™
605 (Agilent Biotechnology, Cat No. 103275-100). Metabolic stress was induced by simultaneous
606 treatment with 1µM Oligomycin and 0.125µM Carbonyl cyanide p-[trifluoromethoxy]-phenyl-
607 hydrazone (FCCP).

608 BeWO cells were also plated onto glass coverslips in 24 well plates at a density of 30,000
609 cells/well. After exposure to ethanol and/or forskolin in culture, cells were prepared for calcium
610 imaging. After replacement of culture media with external imaging media (154 mM NaCl, 5 mM
611 KCl, 2 mM CaCl₂, 0.5 mM MgCl₂, 5 mM glucose, 10 mM HEPES, pH 7.4), cells were loaded for 35
612 minutes at 37°C with the calcium indicator dye fluo-4 AM (Thermo Fisher Scientific, Cat No.
613 F14201), at a final concentration of 5µM fluo-4 AM in 0.1% DMSO. After incubation, cells were
614 washed to remove remaining extracellular fluo-4 and imaged at 40x using confocal microscopy
615 (FV1200-equipped BX61WI microscope, Olympus Corporation, Center Valley, PA). Time-lapse
616 images were acquired at a frequency of 0.5Hz. Individual cells were manually outlined and area

617 and mean fluorescence intensity were obtained for each cell (FIJI image processing
618 package)(105) . To determine the functional calcium range of each cell, at the end of imaging,
619 cells were exposed to 5 μM ionomycin and 10 mM EGTA (0mM external Ca^{2+} , $F_{\text{range}} = F_{\text{ionomycin}} -$
620 F_{EGTA}). Baseline fluorescence was determined by averaging the lowest 5 consecutive
621 fluorescence values during the initial 5 minutes (F_{baseline}) which was then expressed as a
622 percentage of F_{range} ($\Delta F_{\text{baseline}} = (F_{\text{baseline}} - F_{\text{EGTA}}) / F_{\text{range}} \times 100$). Maximal intracellular calcium
623 response to 100 μM ATP was determined by averaging the highest 3 consecutive fluorescence
624 values during ATP application (F_{ATP}) and determining the amount of fluorescence as a
625 percentage of F_{range} ($\Delta F_{\text{ATP}} = (F_{\text{ATP}} - F_{\text{EGTA}}) / F_{\text{range}} \times 100$).

626 Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) analysis:

627 Total RNA was extracted from tissue, well as BeWO and HTR8 cells, using the miRNeasy Mini kit
628 (Qiagen, Cat No. 217004). For miRNA qPCR assays, cDNA was synthesized from 200 ng of total
629 RNA using the miRCURY LNA Universal RT cDNA synthesis kit (Exiqon, Cat No. 203301/Qiagen,
630 Cat No. 339340, Germantown, MD) and expression was assessed using miRCURY LNA SYBR
631 Green (Exiqon, Cat No. 203401/Qiagen, Cat No. 339345). For mRNA qPCR assays, cDNA was
632 synthesized from 500 ng of total RNA using the qScript™ cDNA Synthesis Kit (Quanta/Qiagen,
633 Cat No. 95047). Gene expression analysis was performed using PerfeCTa SYBR Green FastMix
634 (Quanta, Cat No. 95073) on the ViiA 7 Real-Time PCR System (Thermo Fisher Scientific). The
635 data presented correspond to the mean $2^{-\Delta\Delta\text{Ct}}$ after being normalized to the geometric mean of
636 β -actin, Hypoxanthine-Guanine Phosphoribosyltransferase 1 (HPRT1), and 18s rRNA. Expression
637 data for miRNA was normalized to the geometric mean of miR-25-3p, miR-574-3p, miR-30b-5p,
638 miR-652-3p, and miR-15b-5p. For each primer pair, thermal stability curves were assessed for

639 evidence of a single amplicon and the length of each amplicon was verified using agarose gel
640 electrophoresis. A list of primers and their sequences is presented in Supplementary Table 1.
641 Western immunoblotting analysis:
642 Protein was extracted using 1X RIPA lysis buffer (Millipore Sigma, Burlington MA) supplemented
643 with Halt protease inhibitor cocktail (Thermo Fisher Scientific). Tissue was homogenized using
644 the Branson Sonifier 150. Protein concentration was determined using Pierce BCA protein assay
645 kit (Thermo Fisher Scientific) and 30 μ g of protein was loaded onto a 4-12% Bis-Tris
646 (Invitrogen/Thermo Fisher Scientific, Cat No. NPO323BOX), size fractionated at 200 V for 35
647 minutes, and transferred to a PVDF membrane using the iBlot transfer system
648 (Invitrogen/Thermo Fisher Scientific). Blots with protein from cultured cells were blocked with
649 5% nonfat dry milk in tris-buffered saline containing Tween[®]-20 (TTBS) for 1-hour and
650 incubated overnight with primary antibody. The blot was then washed and incubated with an
651 HRP-conjugated goat anti-rabbit or anti-mouse IgG (Invitrogen) at dilution 1:1000 for 1-hour,
652 then developed using PerkinElmer Western Lightning Plus Chemi ECL (PerkinElmer; Waltham,
653 MA) and visualized using a CCD camera (Fluorchem Q, Alpha Innotech; San Leandro, CA). Blots
654 with protein from homogenized tissue were dried overnight, rehydrated in methanol, stained
655 with REVERT™ Total Protein Stain and developed with the Odyssey CLx Imaging System (LI-COR,
656 Lincoln, NE). Blots were then blocked with Odyssey[®] Blocking Buffer (TBS) for 1h and incubated
657 overnight with primary antibody. The blot was then washed and incubated with IRDye[®] 800CW
658 secondary antibody (LI-COR, Cat No. 925-32210). The following antibodies were used: β -Actin
659 HRP (Santa Cruz Biotechnology, Cat No. sc-47778); Goat anti-Mouse IgG (H+L) Secondary
660 Antibody, HRP (Thermo Fisher, Cat No. 62-6520); Goat anti-Rabbit IgG (H+L) Secondary

661 Antibody, HRP (Thermo Fisher, Cat No. 65-6120); purified Mouse Anti-E-Cadherin (BD
662 Biosciences, Cat No. 610181), Rabbit anti-vimentin antibody [EPR3776] (Abcam, Cat No. ab
663 924647). Protein levels were quantified using the densitometric analysis package in FIJI image
664 processing software (105).

665 ELISA:

666 The 2nd and 3rd trimester maternal plasma samples were collected as part of a longitudinal
667 cohort study conducted in two regions of Western Ukraine as part of the Collaborative Initiative
668 on Fetal Alcohol Spectrum Disorders (CIFASD.org) between the years 2006 and 2011, as
669 previously reported(8). Plasma, at a 1:1000 dilution, was subjected to hCG detection using
670 Abcam's intact human hCG ELISA kit (Cat no. ab100533) following the manufacturer's protocol.

671 Literature Review

672 We conducted a literature review for _{HEa}miRNAs and their associated gestational pathology
673 using the National Institute of Health's Pubmed search interface. For each miRNA, the following
674 search parameters were used:

675 *[miRX OR miR X OR miRNA X OR miRNAX or miRNX] AND MeSH Term*

676 where X represents the miRNA of interest and automatic term expansion was enabled. The
677 following MeSH terms, and related search terms (in brackets), were used: Fetal Growth
678 Retardation [Intrauterine Growth Retardation, IUGR Intrauterine Growth Restriction, Low Birth
679 Weight, LBW, Small For Gestational Age, SGA], Premature Birth [Preterm Birth, Preterm Birth,
680 Preterm Infant, Premature Infant, Preterm Labor, Premature Labor], Spontaneous Abortion
681 [Early Pregnancy Loss, Miscarriage, Abortion, Tubal Abortion, Aborted Fetus], Pre-Eclampsia
682 [Pre Eclampsia, Preeclampsia, Pregnancy Toxemia, Gestational Hypertension, Maternal

683 Hypertension], and Maternal Exposure [Environmental Exposure, Prenatal Exposure]. Returned
684 articles were subsequently assessed for relevance.

685 Secondary analysis of RNA sequencing data:

686 Expression levels of _{HEa}miRNAs in tissues were determined using the Human miRNA Expression
687 Database and the miRmine Human miRNA expression database(58, 106). For expression
688 analysis of _{HEa}miRNA pri-miRNAs, RNA sequencing data was used from NCBI's sequence read
689 archive (<https://www.ncbi.nlm.nih.gov/sra>). The accession numbers for the sequence files are:
690 uterus (SRR1957209), thyroid (SRR1957207), thymus (SRR1957206), stomach (SRR1957205),
691 spleen (SRR1957203), small intestine (SRR1957202), skeletal muscle (SRR1957201), salivary
692 gland (SRR1957200), placenta (SRR1957197), lung (SRR1957195), liver (SRR1957193), kidney
693 (SRR1957192), heart (SRR1957191), whole brain (SRR1957183), adrenal gland (SRR1957124),
694 bone marrow (ERR315396), colon (ERR315484), adipose tissue (ERR315332), and pancreas
695 (ERR315479). Deep sequencing analysis was conducted using the Galaxy version 15.07 user
696 interface according to the bioinformatics pipeline outlined in Supplementary Figure 1.

697 Statistical analyses:

698 Linear regression models were used to estimate associations between infant growth measures
699 and miRNA expression levels, gestational age at blood draw, the interaction between subject-
700 centered miRNA expression level and gestational age at blood draw, and child sex. Spearman
701 correlations between infant growth measures and subject-centered miRNA expression levels
702 were also calculated. Linear regression models were also used to estimate the associations
703 between gestational at birth and log-transformed hCG levels, ethanol intake, the interaction
704 between log-transformed hCG levels and ethanol intake, gestational at blood draw, and child

705 sex. Statistical Analysis and graphs were generated with GraphPad Prism 6 software (GraphPad
706 Software, Inc., La Jolla, CA), SPSS v24, or R version 3.3.1. Results are expressed as the mean \pm
707 SEM, or alternatively as box-and-whisker plots with the bounds of the box demarcating limits of
708 1st and 3rd quartile, a median line in the center of the box, and whiskers representing the total
709 range of data. The overall group effect was analyzed for significance using 1-way MANOVA, 1-
710 way or 2-way ANOVA with Tukey's Honest Significance Difference (HSD) or Dunnett's Multiple
711 Comparisons post-hoc testing when appropriate (i.e. following a significant group effect in 1-
712 way ANOVA or given a significant interaction effect between experimental conditions in 2-way
713 ANOVA), to correct for a family-wise error rate. A 2-tailed Student's t-test was used for planned
714 comparisons. For experiments characterizing the individual effects of HEa miRNAs against the
715 control miRNA or antagomirs, individual 2-tailed Student's t-test with 5% FDR correction was
716 applied to account for multiple comparisons. All statistical tests, sample-sizes, and post-hoc
717 analysis are appropriately reported in the results section. A value of $p < 0.05$ was considered
718 statistically significant, and a value of $0.1 < p < 0.05$ was considered marginally significant.

719 Study approval:

720 Human study protocols were approved by Institutional Review Boards at the Lviv National
721 Medical University, Ukraine, and the University of California San Diego as well as Texas A&M
722 University in the USA. Research was conducted according to the principles expressed in the
723 Declaration of Helsinki with written informed consent received from participants prior to
724 inclusion in the study. All rodent experiments were performed in accordance with protocols
725 approved by the University of New Mexico Institutional Animal Care and Use Committee
726 (IACUC), and the Texas A&M University IACUC. All procedures involving non-human primate

727 research subjects were approved by the IACUC of the Oregon National Primate Research Center
728 (ONPRC), and guidelines for humane animal care were followed. The ONPRC abides by the
729 Animal Welfare Act and Regulations enforced by the US Department of Agriculture.

730 Acknowledgements:

731 This research was supported by grants from the NIH, P50 AA022534 (AMA), U01 AA014835 and
732 the Office of Dietary Supplements (CDC), R24 AA019431 (KAG), R01 AA021981 (CDK), R01
733 AA024659 (RCM), F31 AA026505 (AMT) and support from National Health and Medical
734 Research Council of Australia (KMM). We thank CIFASD for intellectual support and Megan S.
735 Pope and Tenley E. Lehman for their assistance in conducting cell culture and animal studies.
736 Data on human subjects is deposited at CIFASD.org, in accordance with NIH data repository
737 guidelines.

738 Author contributions:

739 AT, RM, and CC conceived of and planned the study. AT, AM, and NS designed and conducted
740 cell culture studies, and AT conducted *in vivo*, murine miRNA overexpression studies and
741 analyzed tissues from mouse, rat and primate PAE models. AA developed the mouse PAE model
742 and LA and KM developed the rat PAE model and provided tissues. VR, NN, CK and KG
743 developed the non-human primate model of PAE and provided RNA from microdissected
744 tissues. AW and CC performed statistical analyses of human studies. AT, AM and RCM
745 collaborated on all other statistical analyses. AT, AM, AW, NS, AA, VR, NN, CK, KG, CC, and RM
746 collaborated in preparing the manuscript.

747 Conflict of Interest Statement:

748 The authors have declared that no conflict of interest exists.

749 **Figure Legends**

750 **Figure 1: $_{HEa}$ miRNAs are placentally enriched and associated with gestational pathologies**

751 **A)** Venn diagram on number of $_{HEa}$ miRNAs reported to be associated with different gestational
752 pathologies. Inset colored circles represent the corresponding sex and gestational age-adjusted
753 growth parameters these miRNAs were correlated with. Of the 22 studies queried, 11 (50%)
754 utilized unbiased screenings for miRNA expression.

755 **B)** Heatmap of mature $_{HEa}$ miRNA expression and **C)** pri- $_{HEa}$ miRNA expression across different
756 tissues resulting from secondary analysis of publicly available RNA-sequencing data. Legend
757 depicts row-centered Z-score.

758

759 **Figure 2: $_{HEa}$ miRNAs mediate the effect of PAE on EMT pathway members in mouse and
760 macaque placentas.**

761 **A)** Histological image of GD14 mouse placenta. Outlined in red is the labyrinth zone, blue is the
762 junctional zone, black is the decidual zone. Inset is a high magnification image of the labyrinth
763 zone.

764 **B)** MANOVA of gene expression of core EMT pathway members in different regions of the
765 mouse placenta in control and PAE mice (n=29 samples).

766 **C)** MANCOVA of gene expression of core EMT pathway members in the mouse placental
767 labyrinth zone before (Basic Model) and after accounting for the expression of $_{HEa}$ miRNAs (n=29
768 samples).

769 **D)** Gross anatomy photograph of the primary (left) and secondary (right) lobes of a GD135
770 macaque placenta. Outlined in red is an individual cotyledon from the secondary lobe. Inset is a
771 full thickness hematoxylin and eosin stained histological section of a representative cotyledon
772 with the fetal membranes outlined in black, villous tissue outlined in red and maternal decidua
773 in blue.

774 **E)** MANCOVA of gene expression of core EMT pathway members in placental cotyledons of PAE
775 and control macaques, accounting for the expression of $_{HEa}$ miRNAs collectively (n=23 samples).

776 **F)** MANCOVA of gene expression of core EMT pathway members in macaque placentas after
777 accounting for expression of $_{HEa}$ miRNAs individually (n=23 samples).

778

779 **Figure 3: PAE interferes with the EMT pathway in mouse and macaque placentas**

780 Expression of **A) *CDH1*, B) *VIM*, C) *SNAI1*, D) *TWIST*, and E) *SNAI2*** in the placental labyrinth zone
781 of PAE and control mice (n=5-12 samples per group).

782 **F)** Densitometric quantification of E-Cadherin expression in the labyrinth zone of PAE and
783 control mice as well as representative blot of E-Cadherin expression and total protein
784 expression (right, n=5-12 samples per group).

785 Expression of **G) *CDH1*, H) *VIM*, I) *SNAI2*, and J) *TWIST*** transcripts in PAE and Control macaque
786 placental cotyledons (n=3-5 samples per group).

787 Results are expressed as the mean \pm SEM, LDR=Molecular Weight Ladder; ANOVA: significant
788 main effect of PAE [$^{\square}$ p<0.05, $^{\square\square\square}$ p<0.001], significant interaction effect (sex by PAE, [† p<0.05]).

789 For post-hoc analysis, *** p<0.001 by Tukey's HSD.

790

791 **Figure 4: _{HEa} miRNAs interfere with the EMT pathway in BeWO cytotrophoblasts**

792 **A)** Diagram of a placental anchoring villous and maternal decidua with the boxed area denoting
793 cytotrophoblasts.

794 Expression of **B) *CDH1*, C) *VIM*, D) *TWIST*, and E) *SNAI1*** transcripts **F)** and densitometric
795 quantification of E-Cadherin protein levels in BeWO cytotrophoblasts following _{HEa} miRNAs or

796 control miRNA overexpression with or without concomitant 320 mg/dL ethanol exposure.

797 **G)** Expression of *CDH1*, **H) *VIM*, I) *TWIST*, and J) *SNAI1*** transcripts **K)** and densitometric
798 quantification of E-Cadherin protein levels in BeWO cytotrophoblasts following _{HEa} miRNAs or

799 control hairpin inhibitor transfection with or without concomitant 320 mg/dL ethanol exposure.

800 Results are expressed as the mean \pm SEM, LDR=Molecular Weight Ladder, n=10 samples per

801 group; ANOVA: significant main effect of _{HEa}miRNA transfection [####p<0.0001], significant

802 interaction effect (_{HEa}miRNA by 320mg/dL ethanol, [[†]p<0.05, ^{†††}p<0.001]). For post-hoc analysis

803 *p<0.05, **p<0.01 by Tukey's HSD.

804

805 **Figure 5: _{HEa} miRNAs interfere with the EMT pathway in HTR8 extravillous trophoblasts**

806 **A)** Diagram of a placental anchoring villous and maternal decidua with the boxed area denoting
807 extravillous trophoblasts.

808 Expression of **B) *SNAI2* C) *VIM* D) *TWIST* and E) *SNAI1*** transcripts **F)** as well as densitometric
809 quantification of Vimentin protein levels in HTR8 extravillous trophoblasts following _{HEa} miRNAs

810 or control miRNA overexpression with or without concomitant 320 mg/dL ethanol exposure.

811 Expression of **G) *SNAI2* H) *VIM* I) *TWIST* and J) *SNAI1*** transcripts **K)** as well as densitometric

812 quantification of Vimentin protein levels in HTR8 extravillous trophoblasts following _{HEa} miRNA

813 or control hairpin inhibitor transfection with or without concomitant 320 mg/dL ethanol

814 exposure.

815 Results are expressed as the mean \pm SEM, LDR=Molecular Weight Ladder, n=10 samples per

816 group; ANOVA: significant main effect of _{HEa}miRNA transfection [^{##}p<0.01, #####p<0.0001],

817 significant main effect of 320mg/dL ethanol exposure [^{□□}p<0.01], significant interaction effect

818 (_{HEa}miRNA by 320mg/dL ethanol, [[†]p<0.05, ^{††}p<0.01]). For post-hoc analysis *p<0.05, **p<0.01,

819 ***p<0.001, and ****p<0.0001 by Tukey's HSD.

820

821 **Figure 6: Antagomirs prevent _{HEa} miRNA induced impairment of EMT**

822 Expression of **A) *CDH1* B) *VIM* C) *TWIST* and D) *SNAI1*** transcripts following control or _{HEa} miRNA

823 hairpin inhibitor transfection followed by control or _{HEa} miRNA overexpression in BeWO

824 cytotrophoblasts.

825 Expression of **E) *CDH1* F) *VIM* G) *TWIST* and H) *SNAI1*** transcripts following control or _{HEa} miRNA

826 antagomir transfection followed by control or _{HEa} miRNA overexpression in HTR8 extravillous

827 trophoblasts.

828 In subheadings: **C** denotes control miRNA mimic or hairpin whereas **T** denotes _{HEa} miRNA mimic

829 or hairpin inhibitor. Results are expressed as expressed as the mean \pm SEM, n=10 samples per

830 group; ANOVA: significant treatment effect [^{##}p<0.01, ^{###}p<0.001, ^{####}p<0.0001]. For post-hoc

831 analysis, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by Tukey's HSD.

832

833 **Figure 7: $_{HEa}$ miRNA impair extravillous trophoblast invasion**

834 Transwell invasion of HTR8 extravillous trophoblasts following transfection with **A)** $_{HEa}$ miRNA
835 mimics or **B)** hairpin inhibitors with or without concomitant 320 mg/dL ethanol exposure.
836 O.D. = optical density, results are expressed as expressed as the mean \pm SEM; n=10 samples per
837 group; *p<0.05 by Unpaired T-test

838

839 **Figure 8: $_{HEa}$ miRNA cause cell cycle retardation in trophoblasts**

840 **A)** Degree of EdU incorporation following control and $_{HEa}$ miRNA overexpression.
841 **B)** Degree of EdU incorporation following control and $_{HEa}$ miRNA hairpin inhibitor transfection.
842 **C)** Box and whisker plot for the proportion of cells in G_0/G_1 , S, or G_2/M phase of the cell cycle
843 following control and $_{HEa}$ miRNA overexpression.
844 **D)** Box and whisker plot for the proportion of cells in G_0/G_1 , S, or G_2/M phase of the cell cycle
845 following control and $_{HEa}$ miRNA hairpin inhibitor transfection with or without concomitant 320
846 mg/dL ethanol exposure.
847 For box and whisker plots, bounds of box demarcate limits of 1st and 3rd quartile, line in middle
848 is the median, and whiskers represent the range of data. Representative flow cytometry
849 experiment images are shown on the right.
850 n=10 samples per group; ANOVA: significant main effect of $_{HEa}$ miRNA transfection [$^{##}$ p<0.01,
851 $^{###}$ p<0.001, and $^{####}$ p<0.0001].

852

853 **Figure 9: Antagomirs prevent $_{HEa}$ miRNA induced cell cycle retardation**

854 **A)** Degree of EdU incorporation following control or $_{HEa}$ miRNA hairpin inhibitor transfection
855 followed by control or $_{HEa}$ miRNA overexpression in BeWO cytotrophoblasts. Results are
856 expressed as expressed as the mean \pm SEM.
857 **B)** Box and whisker plot for the proportion of cells in G_0/G_1 , S, or G_2/M phase of the cell cycle
858 following control or $_{HEa}$ miRNA hairpin inhibitor transfection followed by control or $_{HEa}$ miRNA
859 overexpression in BeWO cytotrophoblasts. Bounds of box demarcate limits of 1st and 3rd
860 quartile, line in middle is the median, and whiskers represent the range of data. Representative
861 flow cytometry experiment images are shown on the right.
862 In subheadings: **C** denotes control miRNA mimic or hairpin whereas **T** denotes $_{HEa}$ miRNA mimic
863 or hairpin inhibitor. n=5 samples per group; ANOVA: significant treatment effect [$^{###}$ p<0.001].
864 For post-hoc analysis, **p<0.01 by Tukey's HSD.

865

866 **Figure 10: $_{HEa}$ miRNAs modulate differentiation-associated Ca^{2+} dynamics but have minimal
867 effect on the cellular energetics profile**

868 **A)** Time-lapse confocal images of BeWO cytotrophoblasts loaded with fluo-4 Ca^{2+} indicator dye
869 under indicated treatment conditions. Arrowhead indicates a fused, multinuclear cell, scale bar
870 is 50 μ m.

871 **B)** Box and whisker plot of intracellular calcium levels following acute ATP administration in
872 BeWO cytotrophoblasts with control and $_{HEa}$ miRNA overexpression with or without concomitant
873 320 mg/dL ethanol exposure. Bounds of box demarcate limits of 1st and 3rd quartile, line in
874 middle is the median, and whiskers represent the range of data.
875 **C)** Box and whisker plot of intracellular calcium levels following acute ATP administration in
876 BeWO cytotrophoblasts with control and $_{HEa}$ miRNA overexpression with or without 20 μ m
877 forskolin treatment.
878 **D)** Baseline oxygen consumption rate (OCR), **E)** baseline extracellular acidification rate (ECAR), **F)**
879 stressed OCR, and 10G) stressed ECAR in BeWO cytotrophoblasts with control and $_{HEa}$ miRNA
880 overexpression with or without concomitant 320mg/dL ethanol exposure. Metabolic stress was
881 induced by treatment with 1 μ m Oligomycin and 0.125 μ M (FCCP). Results are expressed as
882 expressed as the mean \pm SEM.
883 n=10 samples per group; ANOVA: significant main effect of 320mg/dL ethanol exposure
884 [[□]p<0.05, ^{□□}p<0.001], significant interaction effect ($_{HEa}$ miRNA by 320mg/dL ethanol, [[†]p<0.05,
885 ^{††}p<0.01, and ^{†††}p<0.0001]). For post-hoc analysis, *p<0.05, **p<0.01, ***p<0.001, and
886 ***p<0.0001 by Tukey's HSD.

887

888 **Figure 11: $_{HEa}$ miRNAs promote syncytialization dependent hCG production**

889 **A)** Diagram of a placental anchoring villous and maternal decidua with the boxed area denoting
890 syncytiotrophoblasts.

891 Expression of **B)** *CGA*, **C)** *CGB*, **D)** *IGF2*, and **E)** *CDH1* transcripts **F)** and densitometric
892 quantification of E-Cadherin protein levels in BeWO cytotrophoblasts following $_{HEa}$ miRNAs or
893 control miRNA overexpression with or without 20 μ m forskolin treatment.

894 Expression of **G)** *CGA*, **H)** *CGB*, **I)** *IGF2*, and **J)** *CDH1* transcripts **K)** and densitometric
895 quantification of E-Cadherin protein levels in BeWO cytotrophoblasts following $_{HEa}$ miRNAs or
896 control hairpin inhibitor transfection with or without 20 μ m forskolin treatment.

897 Results are expressed as expressed as the mean \pm SEM, LDR=Molecular Weight Ladder, n=10
898 samples per group; ANOVA: significant main effect of $_{HEa}$ miRNA transfection [^{#####}p<0.0001],
899 significant interaction effect ($_{HEa}$ miRNA by 320mg/dL ethanol, [[†]p<0.05]). For post-hoc analysis,
900 *p<0.05, **p<0.01 by Tukey's HSD.

901

902 **Figure 12: PAE elevates 3rd trimester maternal hCG**

903 Box and whisker plot of 2nd and 3rd trimester maternal hCG levels in UE, HEua, and HEa group
904 mothers of our Ukrainian birth cohort. Bounds of box demarcate limits of 1st and 3rd quartile,
905 line in middle is the median, and whiskers represent the range of data.

906 Results are expressed as expressed as the mean \pm SEM, n=22-23 samples per group; *p=0.03
907 (Mood's Median Test, $\chi^2=7.043$, df=2).

908

909 **Figure 13: $_{HEa}$ miRNAs restrict fetal growth**

910 **A)** Schematic for measures of crown rump length (CRL), biparietal diameter (BPD), and snout-
911 occipital distance (SOD).

912 **B)** Fetal weight, **C)** crown-rump length, **D)** biparietal diameter, **E)** snout-occipital distance, **F)** and
913 placental weight at GD18 following administration of control (Ctrl) and $_{HEa}$ miRNA mimics to
914 pregnant C57/Bl6 dams on GD10. Dots represent median measures of fetal size and placental
915 weights from male and female offspring in independent litters. There were no significant
916 differences in litter sizes [Ctrl: 8.2 and $_{HEa}$ miRNAs: 8.5] or sex ratios [Ctrl: 0.86 and $_{HEa}$ miRNAs:
917 1.21] between treatment conditions ($p > 0.5$ for all measures).
918 Results are expressed as expressed as the mean \pm SEM, n=5-6 separate litters per treatment
919 condition; ANOVA: significant main effect of $_{HEa}$ miRNA administration [$^{\#}p < 0.05$ and $^{\#\#}p < 0.01$].
920

921 **Figure 14:** $_{HEa}$ miRNAs interfere with EMT in the placenta

922 Expression of **A)** *CDH1* **B)** *VIM* **C)** *TWIST* **D)** *SNAI1* and **E)** *Snai2* and **F)** *SynB* transcripts in GD18
923 placenta following administration of control (Ctrl) and $_{HEa}$ miRNA mimics to pregnant C57/Bl6
924 dams on GD10.
925 Dots represent median expression values of male and female offspring in independent litters.
926 Results are expressed as expressed as the mean \pm SEM, n=5-6 separate litters per treatment
927 condition, ANOVA: significant main effect of $_{HEa}$ miRNA administration [$^{\#}p < 0.05$, $^{\#\#\#}p < 0.001$],
928 significant interaction effect (fetal sex by $_{HEa}$ miRNA administration, [$^{\dagger}p < 0.05$]). For post-hoc
929 analysis, $^*p < 0.05$ by Tukey's HSD.
930

931 **Supplementary Figure Legends**

932

933 **Supplementary Figure 1: Bioinformatics pipeline used to analyze H_{Ea} miRNA pri-miRNA**
934 **expression in tissues.**

935

936 **Supplementary Figure 2: PAE paradigms in mouse, rat, and macaques**

937 **A)** Timeline of mouse alcohol administration

938 **B)** Timeline of rat alcohol administration

939 **C)** Timeline of macaque alcohol administration

940

941 **Supplementary Figure 3: PAE does not impair EMT in mouse placenta junctional and decidual**
942 **zones**

943 **A)** Densitometric quantification of E-cadherin protein levels in junctional and **B)** decidual zone
944 of control and PAE GD14 mice.

945 Results are expressed as expressed as the mean \pm SEM, n=5-12 samples per group.

946

947 **Supplementary Figure 4: PAE and expression of core EMT transcripts in rat placenta**

948 **A)** Expression of CDH1, **B)** Snai1, **C)** VIM, **D)** Snai2, and **E)** TWIST in the placental labyrinth zone
949 of PAE and control rats.

950 Results are expressed as expressed as the mean \pm SEM, n=8 samples per group; ANOVA:
951 significant main effect of PAE [$\#p<0.05$].

952

953 **Supplementary Figure 5: Individual H_{Ea} miRNAs do not affect EMT pathway in BeWO**
954 **cytotrophoblasts**

955 Heatmap for expression of core members of the EMT pathway following overexpression of
956 individual H_{Ea} miRNAs or a control (ctrl) miRNA. Scale for heatmap coloration, right, depicts row-
957 centered Z-score, n=10 samples per group.

958

959 **Supplementary Figure 6: H_{Ea} miRNAs subpools have different effect on the EMT pathway in**
960 **BeWO cytotrophoblasts**

961 **A)** Venn diagram with the diamond indicating H_{Ea} miRNAs broadly implicated in gestational
962 pathologies and the triangle outlining miRNAs implicated in preeclampsia and fetal growth
963 restriction.

964 Expression of **B)** *CDH1* **C)** *VIM* **D)** *TWIST* and **E)** *SNAI1* transcripts following control (**C**), [hsa-miR-
965 222-5p and hsa-miR-519a-3p] (GP), or [hsa-miR-885-3p, hsa-miR-518f-3p, and hsa-miR-204-5p]
966 (PE/FGR) overexpression. Results are expressed as expressed as the mean \pm SEM, n=5 samples
967 per group; ANOVA: significant treatment effect [$\#p<0.05$, $###p<0.001$]. For post-hoc analysis,
968 $*p<0.05$, $**p<0.01$, and $****p<0.0001$ by Dunnett's Multiple Comparisons.

969 **Supplementary Figure 7: Ethanol does not directly affect extravillous trophoblast invasion**

970 Transwell Invasion of HTR8 Extravillous Trophoblasts following 0, 60, 120, and 320mg/dL
971 ethanol exposure.

972 O.D. = optical density, results are expressed as expressed as the mean \pm SEM, n=8 samples per
973 group.

974

975 **Supplementary Figure 8: Ethanol and $_{HEa}$ miRNAs interfere with trophoblast cell cycle dynamics**

976 **A)** Heatmap for degree of EdU incorporation in BeWO cytotrophoblasts following individual
977 $_{HEa}$ miRNA overexpression (top, OE) or transfection with individual $_{HEa}$ miRNA hairpin inhibitors
978 (bottom, HI). Scale for heatmap coloration, right, denotes fold change of EdU incorporation
979 intensity relative to control mimic or hairpin transfection. N=6 samples per group, white
980 asterisks denote $_{HEa}$ miRNA mimics or hairpin inhibitors that had a significant effect, $p < 0.05$,
981 Student's T-test, on degree of EdU incorporation.

982 **B)** Degree of EdU incorporation in BeWO cytotrophoblasts following 0, 60, 120, and 320mg/dL
983 ethanol exposure. n=5 samples per group.

984 **C)** Proportion of BeWO cytotrophoblasts in G_0/G_1 , S, or G_2/M phase of the cell cycle following 0,
985 60, 120, and 320mg/dL ethanol exposure.

986 Results are expressed as expressed as the mean \pm SEM, n=5 samples per group; ANOVA:
987 significant main effect of 320mg/dL ethanol exposure [$p < 0.05$]. For post-hoc analysis, $*p < 0.05$
988 and $**p < 0.01$ by Tukey's HSD.

989

990 **Supplementary Figure 9: $_{HEa}$ miRNAs influence lytic and apoptotic cell death**

991 **A)** Quantification of lytic cell death in BeWO cytotrophoblasts following 0, 60, 120, and
992 320mg/dL ethanol exposure (n=10 samples per group).

993 **B)** Quantification of apoptotic cell death in BeWO cytotrophoblasts following 0, 60, 120, and
994 320mg/dL ethanol exposure (n=8 samples per group).

995 **C)** Heatmap of lytic cell death in BeWO cytotrophoblasts following individual $_{HEa}$ miRNA
996 overexpression (top, OE) or transfection with individual $_{HEa}$ miRNA hairpin inhibitors (bottom,
997 HI). Scale for heatmap coloration, bottom, denotes fold change of lytic cell death relative to
998 control mimic or hairpin transfection. N=10 samples per group, white asterisks denote $_{HEa}$ miRNA
999 mimics or hairpin inhibitors that had a significant effect, $p < 0.05$, Student's t-test, on lytic cell
1000 death.

1001 **D)** Heatmap of apoptotic cell death in BeWO cytotrophoblasts following individual $_{HEa}$ miRNA
1002 overexpression (top, OE) or transfection with individual $_{HEa}$ miRNA hairpin inhibitors (bottom,
1003 HI). Scale for heatmap coloration, bottom, denotes fold change of apoptotic cell death relative
1004 to control mimic or hairpin transfection. N=10 samples per group, white asterisks denote
1005 $_{HEa}$ miRNA mimics or hairpin inhibitors that had a significant effect, $p < 0.05$, Student's t-test, on
1006 apoptosis.

1007 **E)** Quantification of lytic cell death in BeWO cytotrophoblasts following $_{HEa}$ miRNAs or control
1008 miRNA overexpression with or without concomitant 320mg/dL ethanol exposure (n=10 samples
1009 per group).

1010 **F)** Quantification of lytic cell death in BeWO cytotrophoblasts following transfection with
1011 $_{HEa}$ miRNA or control hairpin inhibitors with or without concomitant 320mg/dL ethanol exposure
1012 (n=10 samples per group).

1013 **G)** Quantification of apoptotic cell death in BeWO cytotrophoblasts following $_{HEa}$ miRNA mimics
1014 or control miRNA overexpression with or without concomitant 320mg/dL ethanol exposure
1015 (n=10 samples per group).

1016 **H)** Quantification of apoptotic cell death in BeWO cytotrophoblasts following transfection with
1017 $_{HEa}$ miRNA or control hairpin inhibitors with or without concomitant 320mg/dL ethanol exposure
1018 (n=10 samples per group).

1019 Results are expressed as expressed as the mean \pm SEM; ANOVA: significant main effect of
1020 320mg/dL ethanol exposure [*** p<0.001], significant main effect of $_{HEa}$ miRNA treatment
1021 [$^{##}$ p<0.01].
1022

1023 **Supplementary Figure 10: $_{HEa}$ miRNAs influence differentiation associated Ca^{2+} dynamics**

1024 **A)** Box and whisker plot of BeWO cytotrophoblast size (left) following $_{HEa}$ miRNA overexpression
1025 with or without 20 μ m forskolin treatment.

1026 **B)** Trace of Intracellular Calcium Levels at baseline and following administration of the indicated
1027 compounds, as well as schematic and equations used to calculate relative fluorescence
1028 intensities (n=51-136 cells per group).

1029 **C)** Box and whisker plot baseline intracellular calcium levels in BeWO cytotrophoblasts with
1030 control and $_{HEa}$ miRNA overexpression with or without concomitant 320mg/dL ethanol exposure
1031 (n=69 to 154 samples per group).

1032 **D)** Box and whisker plot of baseline intracellular calcium levels in BeWO cytotrophoblasts with
1033 control and $_{HEa}$ miRNA overexpression with or without 20 μ m forskolin treatment (n=51 to 136
1034 samples per group).

1035 For box and whisker plots, bounds of box demarcate limits of 1st and 3rd quartile, line in middle
1036 is the median, and whiskers represent the range of data; ANOVA: significant interaction effect
1037 (sex by PAE, [† p<0.05, $^{++++}$ p<0.0001]). For post-hoc analysis, *p<0.05 and ***p<0.001 by Tukey's
1038 HSD.
1039

1040 **Supplementary Figure 11: Gestational age at third-trimester maternal blood collection across**
1041 **the UE, HEua, and HEa groups within our Ukrainian birth cohort**

1042 Results are expressed as expressed as the mean \pm SEM, n=22 to 23 samples per group
1043

1044 **Supplementary Figure 12: Biodistribution of miRNAs following systemic administration**

1045 Expression of **A)** miR-518f-3p or **B)** miR-519a-3p in the indicated fetal and maternal
1046 compartments at GD12 following tail vein injection of control (NC) and miR-518f-3p or miR-
1047 519a-3p mimics (P) to pregnant C57/Bl6 dams on GD10.

1048 n=1 sample per group, n.d. indicates non-detectable levels of miRNA.
1049

1050

1051 **Table and Supplementary Table Legends**

1052 **Table 1: H_{Ea} miRNAs are significantly correlated with independent measures of infant size**

1053 The correlation of 2nd and 3rd trimester maternal plasma H_{Ea} miRNA levels with independent
1054 measures of infant size. H_{Ea} miRNAs and their significantly correlated sex and gestational age-
1055 adjusted growth parameters appear in bold. * $p < 0.05$, ** $p < 0.01$.

1056 **Supplementary Table 1: List of primer sequences used**

1057 **Supplementary Table 2: H_{Ea} miRNAs collectively explain the variance in independent measures
1058 of infant size**

1059 R^2 values resulting from a multivariate statistical regression model for 2nd and 3rd trimester
1060 H_{Ea} miRNA levels fit onto sex and gestational-age adjusted growth parameters.

1061
1062 **Supplementary Table 3: Maternal alcohol consumption and hCG levels are negatively
1063 correlated with gestational age at delivery**

1064 Linear regression of gestational age at blood draw, third trimester maternal hCG levels (hCG
1065 level), degree of maternal alcohol consumption, and interaction between hCG levels and
1066 maternal alcohol consumption, with gestational age at delivery as the outcome. For maternal
1067 alcohol consumption: AADO and AADD0 represent absolute ounces of alcohol and absolute
1068 ounces of alcohol per drinking day around conception respectively, whereas AADXP and
1069 AADDXP represent these measures of alcohol consumption during the first trimester. Estimate
1070 represents the computed slope for each variable and C.I. is the confidence interval. * $p < 0.05$,
1071 *** $p < 0.001$

1072

1073 **References**

- 1074 1. Popova S, Lange S, Probst C, Gmel G, and Rehm J. Estimation of national, regional, and global
1075 prevalence of alcohol use during pregnancy and fetal alcohol syndrome: a systematic review and
1076 meta-analysis. *The Lancet Global Health*. 2017;5(3):e290-e9.
- 1077 2. SAMHSA. The NSDUH Report: 18 percent of pregnant women drink alcohol during early
1078 pregnancy. *NSDUH Report*. 2013.
- 1079 3. Bakhireva LN, Sharkis J, Shrestha S, Miranda-Sohrabji TJ, Williams S, and Miranda RC. Prevalence
1080 of Prenatal Alcohol Exposure in the State of Texas as Assessed by Phosphatidylethanol in
1081 Newborn Dried Blood Spot Specimens. *Alcohol Clin Exp Res*. 2017;41(5):1004-11.
- 1082 4. May PA, Chambers CD, Kalberg WO, Zellner J, Feldman H, Buckley D, et al. Prevalence of Fetal
1083 Alcohol Spectrum Disorders in 4 US Communities. *JAMA*. 2018;319(5):474-82.
- 1084 5. Roozen S, Peters GJ, Kok G, Townend D, Nijhuis J, and Curfs L. Worldwide Prevalence of Fetal
1085 Alcohol Spectrum Disorders: A Systematic Literature Review Including Meta-Analysis. *Alcohol
1086 Clin Exp Res*. 2016;40(1):18-32.
- 1087 6. Lange S, Rehm J, Anagnostou E, and Popova S. Prevalence of externalizing disorders and Autism
1088 Spectrum Disorders among children with Fetal Alcohol Spectrum Disorder: systematic review
1089 and meta-analysis. *Biochem Cell Biol*. 2017:1-11.
- 1090 7. Bertrand J, Floyd RL, Weber MK, O'Conner M, Johnson KA, Riley EP, et al. In: US Department of
1091 Health and Human Services ed. Atlanta, GA: CDC; 2004.
- 1092 8. Balaraman S, Schafer JJ, Tseng AM, Wertelecki W, Yevtushok L, Zymak-Zakutnya N, et al. Plasma
1093 miRNA Profiles in Pregnant Women Predict Infant Outcomes following Prenatal Alcohol
1094 Exposure. *PLoS One*. 2016;11(11):e0165081.
- 1095 9. Rossant J, and Cross JC. Placental development: Lessons from mouse mutants. *Nature Reviews
1096 Genetics*. 2001;2:538.
- 1097 10. E. Davies J, Pollheimer J, Yong HEJ, Kokkinos MI, Kalionis B, Knöfler M, et al. Epithelial-
1098 mesenchymal transition during extravillous trophoblast differentiation. *Cell Adhesion &
1099 Migration*. 2016;10(3):310-21.
- 1100 11. Zhou Y, Damsky CH, and Fisher SJ. Preeclampsia is associated with failure of human
1101 cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular
1102 invasion in this syndrome? *The Journal of Clinical Investigation*. 1997;99(9):2152-64.
- 1103 12. Damsky CH, and Fisher SJ. Trophoblast pseudo-vasculogenesis: faking it with endothelial
1104 adhesion receptors. *Current opinion in cell biology*. 1998;10(5):660-6.
- 1105 13. Brown LM, Lacey HA, Baker PN, and Crocker IP. E-cadherin in the assessment of aberrant
1106 placental cytotrophoblast turnover in pregnancies complicated by pre-eclampsia. *Histochemistry
1107 and cell biology*. 2005;124(6):499-506.
- 1108 14. Fedorova L, Gatto-Weis C, Smaili S, Khurshid N, Shapiro JJ, Malhotra D, et al. Down-regulation of
1109 the transcription factor snail in the placentas of patients with preeclampsia and in a rat model of
1110 preeclampsia. *Reprod Biol Endocrinol*. 2012;10:15.
- 1111 15. Blechschmidt K, Mylonas I, Mayr D, Schiessl B, Schulze S, Becker KF, et al. Expression of E-
1112 cadherin and its repressor snail in placental tissue of normal, preeclamptic and HELLP
1113 pregnancies. *Virchows Archiv : an international journal of pathology*. 2007;450(2):195-202.
- 1114 16. Du L, Kuang L, He F, Tang W, Sun W, and Chen D. Mesenchymal-to-epithelial transition in the
1115 placental tissues of patients with preeclampsia. *Hypertension research : official journal of the
1116 Japanese Society of Hypertension*. 2017;40(1):67-72.
- 1117 17. Gundogan F GJ, Ooi JH, Sung J, Qi W, et al. Dual Mechanisms of Ethanol-Impaired Placentation:
1118 Experimental Model. *J Clin Exp Pathol*. 2013;3:142. doi: 10.4172/2161-0681.1000142.

- 1119 18. Tai M, Piskorski A, Kao JCW, Hess LA, M. de la Monte S, and Gündoğan F. Placental Morphology
1120 in Fetal Alcohol Spectrum Disorders. *Alcohol and Alcoholism*. 2017;52(2):138-44.
- 1121 19. Gundogan F, Gilligan J, Qi W, Chen E, Naram R, and de la Monte SM. DOSE EFFECT OF
1122 GESTATIONAL ETHANOL EXPOSURE ON PLACENTATION AND FETAL GROWTH. *Placenta*.
1123 2015;36(5):523-30.
- 1124 20. Gardebjer EM, Cuffe JS, Pantaleon M, Wlodek ME, and Moritz KM. Periconceptional alcohol
1125 consumption causes fetal growth restriction and increases glycogen accumulation in the late
1126 gestation rat placenta. *Placenta*. 2014;35(1):50-7.
- 1127 21. Kalisch-Smith JJ, Outhwaite JE, Simmons DG, Pantaleon M, and Moritz KM. Alcohol exposure
1128 impairs trophoblast survival and alters subtype-specific gene expression in vitro. *Placenta*.
1129 2016;46:87-91.
- 1130 22. Bahado-Singh RO, Oz AU, Kingston JM, Shahabi S, Hsu CD, and Cole L. The role of
1131 hyperglycosylated hCG in trophoblast invasion and the prediction of subsequent pre-eclampsia.
1132 *Prenatal diagnosis*. 2002;22(6):478-81.
- 1133 23. Muller F, Savey L, Le Fiblec B, Bussieres L, Ndayizamba G, Colau JC, et al. Maternal serum human
1134 chorionic gonadotropin level at fifteen weeks is a predictor for preeclampsia. *Am J Obstet
1135 Gynecol*. 1996;175(1):37-40.
- 1136 24. Spencer K, Macri JN, Aitken DA, and Connor JM. Free beta-hCG as first-trimester marker for fetal
1137 trisomy. *Lancet (London, England)*. 1992;339(8807):1480.
- 1138 25. Spencer K. Evaluation of an assay of the free beta-subunit of choriogonadotropin and its
1139 potential value in screening for Down's syndrome. *Clin Chem*. 1991;37(6):809-14.
- 1140 26. Salihi HM, Kornosky JL, Lynch O, Alio AP, August EM, and Marty PJ. Impact of prenatal alcohol
1141 consumption on placenta-associated syndromes. *Alcohol*. 2011;45(1):73-9.
- 1142 27. Khong TY. Placental vascular development and neonatal outcome. *Seminars in neonatology : SN*.
1143 2004;9(4):255-63.
- 1144 28. Ray JG, Vermeulen MJ, Schull MJ, and Redelmeier DA. Cardiovascular health after maternal
1145 placental syndromes (CHAMPS): population-based retrospective cohort study. *Lancet (London,
1146 England)*. 2005;366(9499):1797-803.
- 1147 29. Wang D, Na Q, Song WW, and Song GY. Altered Expression of miR-518b and miR-519a in the
1148 placenta is associated with low fetal birth weight. *American journal of perinatology*.
1149 2014;31(9):729-34.
- 1150 30. Wang JM, Gu Y, Zhang Y, Yang Q, Zhang X, Yin L, et al. Deep-sequencing identification of
1151 differentially expressed miRNAs in decidua and villus of recurrent miscarriage patients. *Archives
1152 of gynecology and obstetrics*. 2016;293(5):1125-35.
- 1153 31. Hromadnikova I, Kotlabova K, Ondrackova M, Pirkova P, Kestlerova A, Novotna V, et al.
1154 Expression profile of C19MC microRNAs in placental tissue in pregnancy-related complications.
1155 *DNA and cell biology*. 2015;34(6):437-57.
- 1156 32. Hromadnikova I, Kotlabova K, Ivankova K, and Krofta L. Expression profile of C19MC microRNAs
1157 in placental tissue of patients with preterm prelabor rupture of membranes and spontaneous
1158 preterm birth. *Molecular medicine reports*. 2017;16(4):3849-62.
- 1159 33. Timofeeva AV, Gusar VA, Kan NE, Prozorovskaya KN, Karapetyan AO, Bayev OR, et al.
1160 Identification of potential early biomarkers of preeclampsia. *Placenta*. 2018;61:61-71.
- 1161 34. Dong F, Zhang Y, Xia F, Yang Y, Xiong S, Jin L, et al. Genome-wide miRNA profiling of villus and
1162 decidua of recurrent spontaneous abortion patients. *Reproduction (Cambridge, England)*.
1163 2014;148(1):33-41.
- 1164 35. Hu Y, Li P, Hao S, Liu L, Zhao J, and Hou Y. Differential expression of microRNAs in the placentae
1165 of Chinese patients with severe pre-eclampsia. *Clinical chemistry and laboratory medicine*.
1166 2009;47(8):923-9.

- 1167 36. Murphy MS, Casselman RC, Tayade C, and Smith GN. Differential expression of plasma
1168 microRNA in preeclamptic patients at delivery and 1 year postpartum. *Am J Obstet Gynecol.*
1169 2015;213(3):367.e1-9.
- 1170 37. Bidarimath M, Edwards AK, Wessels JM, Khalaj K, Kridli RT, and Tayade C. Distinct microRNA
1171 expression in endometrial lymphocytes, endometrium, and trophoblast during spontaneous
1172 porcine fetal loss. *Journal of reproductive immunology.* 2015;107:64-79.
- 1173 38. Liu XD, Wu X, Yin YL, Liu YQ, Geng MM, Yang HS, et al. Effects of dietary L-arginine or N-
1174 carbamylglutamate supplementation during late gestation of sows on the miR-15b/16, miR-
1175 221/222, VEGFA and eNOS expression in umbilical vein. *Amino acids.* 2012;42(6):2111-9.
- 1176 39. Baker BC, Mackie FL, Lean SC, Greenwood SL, Heazell AEP, Forbes K, et al. Placental dysfunction
1177 is associated with altered microRNA expression in pregnant women with low folate status.
1178 *Molecular nutrition & food research.* 2017;61(8).
- 1179 40. Gao Y, She R, Wang Q, Li Y, and Zhang H. Up-regulation of miR-299 suppressed the invasion and
1180 migration of HTR-8/SVneo trophoblast cells partly via targeting HDAC2 in pre-eclampsia.
1181 *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.* 2018;97:1222-8.
- 1182 41. Sandrim VC, Luizon MR, Palei AC, Tanus-Santos JE, and Cavalli RC. Circulating microRNA
1183 expression profiles in pre-eclampsia: evidence of increased miR-885-5p levels. *BJOG : an
1184 international journal of obstetrics and gynaecology.* 2016;123(13):2120-8.
- 1185 42. Rodosthenous RS, Burris HH, Sanders AP, Just AC, Dereix AE, Svensson K, et al. Second trimester
1186 extracellular microRNAs in maternal blood and fetal growth: An exploratory study. *Epigenetics.*
1187 2017;12(9):804-10.
- 1188 43. Martinez-Fierro ML, Garza-Veloz I, Gutierrez-Arteaga C, Delgado-Enciso I, Barbosa-Cisneros OY,
1189 Flores-Morales V, et al. Circulating levels of specific members of chromosome 19 microRNA
1190 cluster are associated with preeclampsia development. *Archives of gynecology and obstetrics.*
1191 2018;297(2):365-71.
- 1192 44. Yang S, Li H, Ge Q, Guo L, and Chen F. Deregulated microRNA species in the plasma and placenta
1193 of patients with preeclampsia. *Molecular medicine reports.* 2015;12(1):527-34.
- 1194 45. Hromadnikova I, Kotlabova K, Ivankova K, and Krofta L. First trimester screening of circulating
1195 C19MC microRNAs and the evaluation of their potential to predict the onset of preeclampsia
1196 and IUGR. *PLOS ONE.* 2017;12(2):e0171756.
- 1197 46. Zhang M, Muralimanoharan S, Wortman AC, and Mendelson CR. Primate-specific miR-515 family
1198 members inhibit key genes in human trophoblast differentiation and are upregulated in
1199 preeclampsia. *Proceedings of the National Academy of Sciences of the United States of America.*
1200 2016;113(45):E7069-E76.
- 1201 47. Nemoto T, Kakinuma Y, and Shibasaki T. Impaired miR449a-induced downregulation of Crhr1
1202 expression in low-birth-weight rats. *The Journal of endocrinology.* 2015;224(2):195-203.
- 1203 48. Mei Z, Huang B, Mo Y, and Fan J. An exploratory study into the role of miR-204-5p in pregnancy-
1204 induced hypertension. *Experimental and therapeutic medicine.* 2017;13(5):1711-8.
- 1205 49. Choi SY, Yun J, Lee OJ, Han HS, Yeo MK, Lee MA, et al. MicroRNA expression profiles in placenta
1206 with severe preeclampsia using a PNA-based microarray. *Placenta.* 2013;34(9):799-804.
- 1207 50. Kaufmann P, Black S, and Huppertz B. Endovascular trophoblast invasion: implications for the
1208 pathogenesis of intrauterine growth retardation and preeclampsia. *Biol Reprod.* 2003;69(1):1-7.
- 1209 51. Barrientos G, Pussetto M, Rose M, Staff AC, Blois SM, and Toblli JE. Defective trophoblast
1210 invasion underlies fetal growth restriction and preeclampsia-like symptoms in the stroke-prone
1211 spontaneously hypertensive rat. *Molecular human reproduction.* 2017;23(7):509-19.
- 1212 52. Roberts JM, and Escudero C. The placenta in preeclampsia. *Pregnancy hypertension.*
1213 2012;2(2):72-83.


- 1214 53. Fisher SJ. Why is placentation abnormal in preeclampsia? *American journal of obstetrics and*
1215 *gynecology*. 2015;213(4 0):S115-S22.
- 1216 54. Crosley EJ, Elliot MG, Christians JK, and Crespi BJ. Placental invasion, preeclampsia risk and
1217 adaptive molecular evolution at the origin of the great apes: evidence from genome-wide
1218 analyses. *Placenta*. 2013;34(2):127-32.
- 1219 55. Lyall F, Bulmer JN, Duffie E, Cousins F, Theriault A, and Robson SC. Human Trophoblast Invasion
1220 and Spiral Artery Transformation : The Role of PECAM-1 in Normal Pregnancy, Preeclampsia, and
1221 Fetal Growth Restriction. *The American Journal of Pathology*. 2001;158(5):1713-21.
- 1222 56. Goldman-Wohl D, and Yagel S. Regulation of trophoblast invasion: from normal implantation to
1223 pre-eclampsia. *Molecular and cellular endocrinology*. 2002;187(1-2):233-8.
- 1224 57. Balaraman S, Lunde ER, Sawant O, Cudd TA, Washburn SE, and Miranda RC. Maternal and
1225 neonatal plasma microRNA biomarkers for fetal alcohol exposure in an ovine model. *Alcohol Clin*
1226 *Exp Res*. 2014;38(5):1390-400.
- 1227 58. Panwar B, Omenn GS, and Guan Y. miRmine: a database of human miRNA expression profiles.
1228 *Bioinformatics*. 2017;33(10):1554-60.
- 1229 59. Vicovac L, and Aplin JD. Epithelial-mesenchymal transition during trophoblast differentiation.
1230 *Acta anatomica*. 1996;156(3):202-16.
- 1231 60. Knöfler M, and Pollheimer J. Human placental trophoblast invasion and differentiation: a
1232 particular focus on Wnt signaling. *Frontiers in Genetics*. 2013;4:190.
- 1233 61. Arimoto-Ishida E, Sakata M, Sawada K, Nakayama M, Nishimoto F, Mabuchi S, et al. Up-
1234 regulation of alpha5-integrin by E-cadherin loss in hypoxia and its key role in the migration of
1235 extravillous trophoblast cells during early implantation. *Endocrinology*. 2009;150(9):4306-15.
- 1236 62. Sun YY, Lu M, Xi XW, Qiao QQ, Chen LL, Xu XM, et al. Regulation of epithelial-mesenchymal
1237 transition by homeobox gene DLX4 in JEG-3 trophoblast cells: a role in preeclampsia.
1238 *Reproductive sciences (Thousand Oaks, Calif)*. 2011;18(11):1138-45.
- 1239 63. Barrak J, Msheik H, Abou-Kheir W, and Daoud G. Assessment of different trophoblast cell lines
1240 as in vitro models for placental development. *Placenta*. 2016;45:106.
- 1241 64. Lovisa S, LeBleu VS, Tampe B, Sugimoto H, Vадnagara K, Carstens JL, et al. Epithelial-to-
1242 mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis.
1243 *Nature medicine*. 2015;21(9):998-1009.
- 1244 65. Vega S, Morales AV, Ocana OH, Valdes F, Fabregat I, and Nieto MA. Snail blocks the cell cycle
1245 and confers resistance to cell death. *Genes & development*. 2004;18(10):1131-43.
- 1246 66. Moreau R, Hamel A, Daoud G, Simoneau L, and Lafond J. Expression of calcium channels along
1247 the differentiation of cultured trophoblast cells from human term placenta. *Biol Reprod*.
1248 2002;67(5):1473-9.
- 1249 67. Lu X, He Y, Zhu C, Wang H, Chen S, and Lin HY. Twist1 is involved in trophoblast syncytialization
1250 by regulating GCM1. *Placenta*. 2016;39:45-54.
- 1251 68. Omata W, Ackerman WEIV, Vandre DD, and Robinson JM. Trophoblast Cell Fusion and
1252 Differentiation Are Mediated by Both the Protein Kinase C and A Pathways. *PLOS ONE*.
1253 2013;8(11):e81003.
- 1254 69. Spaans F, Melgert BN, Chiang C, Borghuis T, Klok PA, de Vos P, et al. Extracellular ATP decreases
1255 trophoblast invasion, spiral artery remodeling and immune cells in the mesometrial triangle in
1256 pregnant rats. *Placenta*. 2014;35(8):587-95.
- 1257 70. Karl PI, Chusid J, Tagoe C, and Fisher SE. Ca²⁺ flux in human placental trophoblasts. *Am J Physiol*.
1258 1997;272(6 Pt 1):C1776-80.
- 1259 71. Roberts VH, Waters LH, and Powell T. Purinergic receptor expression and activation in first
1260 trimester and term human placenta. *Placenta*. 2007;28(4):339-47.

- 1261 72. Halmesmaki E, Autti I, Granstrom ML, Stenman UH, and Ylikorkala O. Estradiol, estriol,
1262 progesterone, prolactin, and human chorionic gonadotropin in pregnant women with alcohol
1263 abuse. *J Clin Endocrinol Metab.* 1987;64(1):153-6.
- 1264 73. Edelstam G, Karlsson C, Westgren M, Lowbeer C, and Swahn ML. Human chorionic gonadatropin
1265 (hCG) during third trimester pregnancy. *Scandinavian journal of clinical and laboratory*
1266 *investigation.* 2007;67(5):519-25.
- 1267 74. Soares MJ, Chakraborty D, Rumi MAK, Konno T, and Renaud SJ. Rat Placentation: An
1268 Experimental Model For Investigating The Hemochorial Maternal-Fetal Interface. *Placenta.*
1269 2012;33(4):233-43.
- 1270 75. Grigsby PL. Animal Models to Study Placental Development and Function throughout Normal
1271 and Dysfunctional Human Pregnancy. *Seminars in reproductive medicine.* 2016;34(1):11-6.
- 1272 76. Vercruyse L, Caluwaerts S, Luyten C, and Pijnenborg R. Interstitial trophoblast invasion in the
1273 decidua and mesometrial triangle during the last third of pregnancy in the rat. *Placenta.*
1274 2006;27(1):22-33.
- 1275 77. Silva JF, and Serakides R. Intrauterine trophoblast migration: A comparative view of humans and
1276 rodents. *Cell Adhesion & Migration.* 2016;10(1-2):88-110.
- 1277 78. Kurtzman JT, Wilson H, and Rao CV. A Proposed Role for hCG in Clinical Obstetrics. *Semin Reprod*
1278 *Med.* 2001;19(01):063-8.
- 1279 79. Furcron A-E, Romero R, Mial TN, Balancio A, Panaitescu B, Hassan SS, et al. Human Chorionic
1280 Gonadotropin Has Anti-Inflammatory Effects at the Maternal-Fetal Interface and Prevents
1281 Endotoxin-Induced Preterm Birth, but Causes Dystocia and Fetal Compromise in Mice. *Biology of*
1282 *Reproduction.* 2016;94(6):136.
- 1283 80. Henderson GI, Hoyumpa AM, Jr., McClain C, and Schenker S. The effects of chronic and acute
1284 alcohol administration on fetal development in the rat. *Alcohol Clin Exp Res.* 1979;3(2):99-106.
- 1285 81. O'Leary-Moore SK, Parnell SE, Godin EA, Dehart DB, Ament JJ, Khan AA, et al. Magnetic
1286 resonance microscopy-based analyses of the brains of normal and ethanol-exposed fetal mice.
1287 *Birth Defects Res A Clin Mol Teratol.* 2010;88(11):953-64.
- 1288 82. Bake S, Tingling JD, and Miranda RC. Ethanol exposure during pregnancy persistently attenuates
1289 cranially directed blood flow in the developing fetus: evidence from ultrasound imaging in a
1290 murine second trimester equivalent model. *Alcohol Clin Exp Res.* 2012;36(5):748-58.
- 1291 83. Lo JO, Schabel MC, Roberts VH, Wang X, Lewandowski KS, Grant KA, et al. First trimester alcohol
1292 exposure alters placental perfusion and fetal oxygen availability affecting fetal growth and
1293 development in a non-human primate model. *Am J Obstet Gynecol.* 2017;216(3):302.e1-e8.
- 1294 84. Xie L, Mouillet J-F, Chu T, Parks WT, Sadovsky E, Knöfler M, et al. C19MC MicroRNAs Regulate
1295 the Migration of Human Trophoblasts. *Endocrinology.* 2014;155(12):4975-85.
- 1296 85. Smith SM, Garic A, Flentke GR, and Berres ME. Neural Crest Development in Fetal Alcohol
1297 Syndrome. *Birth defects research Part C, Embryo today : reviews.* 2014;102(3):210-20.
- 1298 86. Kalcheim C. Epithelial–Mesenchymal Transitions during Neural Crest and Somite Development.
1299 *Journal of Clinical Medicine.* 2016;5(1):1.
- 1300 87. Yang J, Qiu H, Qu P, Zhang R, Zeng L, and Yan H. Prenatal Alcohol Exposure and Congenital Heart
1301 Defects: A Meta-Analysis. *PLoS ONE.* 2015;10(6):e0130681.
- 1302 88. Burd L, Deal E, Rios R, Adickes E, Wynne J, and Klug MG. Congenital heart defects and fetal
1303 alcohol spectrum disorders. *Congenital heart disease.* 2007;2(4):250-5.
- 1304 89. Serrano M, Han M, Brinez P, and Linask KK. Fetal alcohol syndrome: cardiac birth defects in mice
1305 and prevention with folate. *Am J Obstet Gynecol.* 2010;203(1):75.e7-e15.
- 1306 90. Sarmah S, and Marrs JA. Complex cardiac defects after ethanol exposure during discrete
1307 cardiogenic events in zebrafish: Prevention with folic acid. *Developmental dynamics : an official*
1308 *publication of the American Association of Anatomists.* 2013;242(10):1184-201.


- 1309 91. Combs MD, and Yutzey KE. Heart Valve Development: Regulatory networks in development and
1310 disease. *Circulation research*. 2009;105(5):408-21.
- 1311 92. Lin C-J, Lin C-Y, Chen C-H, Zhou B, and Chang C-P. Partitioning the heart: mechanisms of cardiac
1312 septation and valve development. *Development (Cambridge, England)*. 2012;139(18):3277-99.
- 1313 93. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of
1314 HCV infection by targeting microRNA. *The New England journal of medicine*. 2013;368(18):1685-
1315 94.
- 1316 94. Beg MS, Brenner AJ, Sachdev J, Borad M, Kang YK, Stoudemire J, et al. Phase I study of MRX34, a
1317 liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors.
1318 *Invest New Drugs*. 2017;35(2):180-8.
- 1319 95. Sathyan P, Golden HB, and Miranda RC. Competing interactions between micro-RNAs determine
1320 neural progenitor survival and proliferation after ethanol exposure: evidence from an ex vivo
1321 model of the fetal cerebral cortical neuroepithelium. *J Neurosci*. 2007;27(32):8546-57.
- 1322 96. Huang W, Tian SS, Hang PZ, Sun C, Guo J, and Du ZM. Combination of microRNA-21 and
1323 microRNA-146a Attenuates Cardiac Dysfunction and Apoptosis During Acute Myocardial
1324 Infarction in Mice. *Molecular therapy Nucleic acids*. 2016;5:e296.
- 1325 97. Brady ML, Allan AM, and Caldwell KK. A Limited Access Mouse Model of Prenatal Alcohol
1326 Exposure that Produces Long-Lasting Deficits in Hippocampal-Dependent Learning and Memory.
1327 *Alcoholism, clinical and experimental research*. 2012;36(3):457-66.
- 1328 98. Kajimoto K, Allan A, and Cunningham LA. Fate Analysis of Adult Hippocampal Progenitors in a
1329 Murine Model of Fetal Alcohol Spectrum Disorder (FASD). *PLoS ONE*. 2013;8(9):e73788.
- 1330 99. Watson ED, and Cross JC. Development of structures and transport functions in the mouse
1331 placenta. *Physiology (Bethesda)*. 2005;20:180-93.
- 1332 100. Gårdebjer EM, Anderson ST, Pantaleon M, Wlodek ME, and Moritz KM. Maternal alcohol intake
1333 around the time of conception causes glucose intolerance and insulin insensitivity in rat
1334 offspring, which is exacerbated by a postnatal high-fat diet. *The FASEB Journal*. 2015;29(7):2690-
1335 701.
- 1336 101. Grant KA, Leng X, Green HL, Szeliga KT, Rogers LS, and Gonzales SW. Drinking typography
1337 established by scheduled induction predicts chronic heavy drinking in a monkey model of
1338 ethanol self-administration. *Alcohol Clin Exp Res*. 2008;32(10):1824-38.
- 1339 102. Carter AM. Animal models of human placentation--a review. *Placenta*. 2007;28 Suppl A:S41-7.
- 1340 103. Orendi K, Gauster M, Moser G, Meiri H, and Huppertz B. The choriocarcinoma cell line BeWo:
1341 syncytial fusion and expression of syncytium-specific proteins. *Reproduction (Cambridge,
1342 England)*. 2010;140(5):759-66.
- 1343 104. Oh SY, Hwang JR, Lee Y, Choi SJ, Kim JS, Kim JH, et al. Isolation of basal membrane proteins from
1344 BeWo cells and their expression in placentas from fetal growth-restricted pregnancies. *Placenta*.
1345 2016;39:24-32.
- 1346 105. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-
1347 source platform for biological-image analysis. *Nature methods*. 2012;9(7):676-82.
- 1348 106. Gong J, Wu Y, Zhang X, Liao Y, Sibanda VL, Liu W, et al. Comprehensive analysis of human small
1349 RNA sequencing data provides insights into expression profiles and miRNA editing. *RNA biology*.
1350 2014;11(11):1375-85.

1351


1A



1B




1C




2A

bioRxiv preprint doi: <https://doi.org/10.1101/409854>; this version posted February 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.




2B

Mouse




2C

Mouse




2D




2E


Macaque





2F

Macaque













7A





7B













**Syncytiotrophoblasts
(Forskolin-treated BeWO cells)**








Figure 14

